Generic and Brand Names

• Generic Name: L-Arginine (Arginine Hydrochloride)
• Brand Names: R-Gene 10 (diagnostic use); various compounded formulations
• Drug Class: Semi-Essential Amino Acid / Nitric Oxide Precursor
• Route: Intravenous (IV) or intramuscular (IM) injection
• FDA Status: FDA-approved as a diagnostic agent (R-Gene 10) for pituitary function testing. Off-label use for circulation, sexual health, and athletic performance.

Primary Indications/Uses

• Pituitary function diagnostic testing (FDA-approved)
• Nitric oxide production and cardiovascular support (off-label)
• Erectile function support (off-label)
• Athletic performance and blood flow (off-label)
• Wound healing support

Contraindications

• Known hypersensitivity to arginine or any component
• Uncorrected electrolyte imbalances (must be corrected before use)
• Severe hepatic or renal disease
• Concurrent use with nitrate medications (risk of severe hypotension)

Warnings and Precautions

METABOLIC ACIDOSIS: Overdosage can result in hyperchloremic metabolic acidosis, especially in pediatric patients, which can potentially be fatal.

CEREBRAL EDEMA: Reported with overdosage, particularly in pediatric patients.

HYPOTENSION RISK: Arginine promotes nitric oxide production and vasodilation. Combined with nitrates or other vasodilators, this can cause dangerous drops in blood pressure.

HYPERKALEMIA: Arginine can raise potassium levels. Monitor in patients with renal impairment.

HERPES SIMPLEX: Arginine may theoretically promote herpes simplex virus replication. Patients with active or recurrent herpes should use with caution.

MEDICAL SUPERVISION: Must be administered by or under direct supervision of a physician.

Common Side Effects

• Injection site reactions (pain, redness, swelling, bruising, warmth, numbness, stinging)
• Flushing
• Nausea
• Headache
• Numbness/tingling

Serious Adverse Reactions

• Anaphylaxis/hypersensitivity reactions
• Hyperchloremic metabolic acidosis (overdose)
• Severe hypotension (especially with nitrates)
• Cerebral edema (overdose, especially pediatric)
• Hyperkalemia

Drug Interactions

• Nitrate medications (nitroglycerin, isosorbide): Additive vasodilation and risk of severe hypotension -- avoid concurrent use
• Other vasodilators: Additive hypotensive effect
• Dichlorphenamide: Increases toxicity of both drugs through pharmacodynamic synergism (both cause metabolic acidosis)
• Potassium-sparing diuretics: Risk of hyperkalemia
• Anticoagulants: Theoretical additive effect
• Phosphodiesterase-5 inhibitors (sildenafil, tadalafil): Additive vasodilatory effects; use with caution

Special Populations

• Pregnancy: Use only if clearly needed; insufficient data.
• Breastfeeding: Unknown whether excreted in breast milk; weigh benefits vs. risks.
• Pediatric: Risk of hyperchloremic metabolic acidosis and cerebral edema with overdosage.
• Renal Impairment: Use with caution; risk of hyperkalemia and metabolite accumulation.
• Hepatic Impairment: Use with caution.
• Herpes Patients: May theoretically promote viral replication.

Generic and Brand Names

• Generic Name: Vitamin B Complex (typically contains: Thiamine/B1, Riboflavin/B2, Niacinamide/B3, Dexpanthenol/B5, Pyridoxine/B6, and sometimes B12 and Folic Acid)
• Brand Names: Various compounded formulations (e.g., B-Complex 100, Infuvite)
• Drug Class: Water-Soluble Vitamin Complex
• Route: Intramuscular (IM) or intravenous (IV) injection
• FDA Status: Some formulations are FDA-approved as nutritional supplements. Many injectable B-Complex products are compounded.

Primary Indications/Uses

• B-vitamin deficiency states
• Energy support and metabolism
• Nervous system support
• Stress and mood support
• Post-surgical or post-illness nutritional repletion

Contraindications

• Known hypersensitivity to any B vitamin component in the formulation
• Severe hypertension (some B-complex formulations)

Warnings and Precautions

THIAMINE ANAPHYLAXIS: Parenteral thiamine (B1) has historically been associated with anaphylactogenesis, though recent safety analyses suggest the risk is very low in practice. Nonetheless, observe patients during administration and have epinephrine available.

NIACIN FLUSHING: Niacinamide/niacin component may cause flushing, warmth, headache, and transient hypotension.

INJECTION SPEED: Must be injected slowly to reduce risk of adverse reactions.

RIBOFLAVIN URINE COLOR: Riboflavin (B2) causes bright yellow urine discoloration. This is harmless but patients should be informed.

INDIVIDUAL COMPONENT DOSES: Be aware of total B-vitamin intake if patients are also taking oral supplements to avoid excessive intake of specific vitamins.

Common Side Effects

• Injection site soreness, redness, or swelling
• Mild nausea
• Flushing (niacin component)
• Transient headache
• Mild diarrhea
• Bright yellow urine (riboflavin)

Serious Adverse Reactions

• Anaphylaxis/severe allergic reaction (rare, most associated with thiamine)
• Severe hypotension
• Chest pain, difficulty breathing
• Hives or angioedema

Drug Interactions

• Levodopa: Pyridoxine (B6) can reduce the effectiveness of levodopa (but not carbidopa/levodopa combinations)
• Phenytoin: High-dose B6 may reduce phenytoin levels
• Fluorouracil (5-FU): Thiamine may reduce efficacy
• Antibiotics: Broad-spectrum antibiotics may reduce B-vitamin production by gut flora
• Alcohol: Chronic alcohol use depletes B vitamins and may increase need for supplementation
• Metformin: May reduce B12 absorption

Special Populations

• Pregnancy: Generally considered safe at recommended doses. Essential for fetal development.
• Breastfeeding: Generally considered safe.
• Renal Impairment: Water-soluble vitamins are renally excreted; use caution in severe renal impairment.
• Alcoholism: Patients with chronic alcohol use may require higher doses, especially thiamine.

Generic and Brand Names

• Generic Name: Biotin (Vitamin B7, Vitamin H)
• Brand Names: No specific injectable brand names. Available through compounding pharmacies.
• Drug Class: Water-Soluble Vitamin
• Route: Intramuscular (IM) injection
• FDA Status: Biotin is an FDA-recognized vitamin. Injectable formulations are typically compounded.

Primary Indications/Uses

• Biotin deficiency
• Hair, skin, and nail support
• Metabolic support (carboxylase enzyme cofactor)
• Biotinidase deficiency (genetic condition)

Contraindications

• Known hypersensitivity to biotin or any component of the formulation
• No other absolute contraindications on record

Warnings and Precautions

CRITICAL -- LABORATORY TEST INTERFERENCE: High-dose biotin supplementation can significantly interfere with laboratory test results, including:

• Thyroid function tests (may show falsely abnormal results)
• Cardiac troponin assays (may show falsely low troponin, potentially masking heart attack)
• Hormone level tests (various)
• Other immunoassays

Patients MUST inform all healthcare providers and laboratory personnel that they are taking biotin, especially before any blood work. Biotin should be discontinued at least 72 hours before laboratory testing, or as directed by the ordering provider.

PRE-INJECTION PRECAUTIONS: Avoid alcohol 24 hours before injection. Avoid blood thinners, aspirin, or anti-inflammatory medications for 3 days prior to treatment if possible.

VERY WELL TOLERATED: Studies have shown no adverse effects with doses up to 200 mg/day oral or 20 mg/day IV in patients with biotinidase deficiency.

Common Side Effects

• Injection site soreness, redness, or bruising
• Mild nausea
• Diarrhea
• Headache
• Joint pain
• Mild swelling sensation

Serious Adverse Reactions

• Allergic/anaphylactic reaction (very rare)
• Laboratory test interference leading to misdiagnosis (most clinically significant risk)

Drug Interactions

• Anticonvulsants (carbamazepine, phenytoin, phenobarbital, primidone): May decrease biotin levels
• Antibiotics (long-term): May reduce biotin-producing gut flora
• Raw egg whites: Contain avidin, which binds biotin and prevents absorption (dietary, not drug)
• CYP450 substrates: Biotin may decrease how quickly the liver breaks down certain medications, potentially increasing their effects and side effects
• Alpha-lipoic acid: May compete for absorption

Special Populations

• Pregnancy: Marginal biotin deficiency is common during pregnancy. Supplementation generally considered safe at standard doses.
• Breastfeeding: Generally considered safe.
• Pediatric: Used in biotinidase deficiency; generally safe under supervision.
• Renal Impairment: Water-soluble; use caution in severe renal impairment.

Generic and Brand Names

• Generic Name: BPC-157 (Body Protection Compound-157); Pentadecapeptide
• Brand Names: No FDA-approved brand names. Available as compounded peptide from licensed pharmacies.
• Drug Class: Synthetic Peptide (derived from gastric juice protein)
• Route: Subcutaneous or intramuscular injection; also available as oral capsule
• FDA Status: NOT FDA-approved for any indication. Classified as Category 2 bulk drug substance by the FDA (2023), meaning it cannot be compounded by commercial outsourcing facilities. Prohibited by WADA/USADA in competitive athletics.

Primary Indications/Uses (Investigational)

• Tissue repair and wound healing
• Tendon, ligament, and muscle injury recovery
• Gastrointestinal protection and healing (ulcers, IBD support)
• Anti-inflammatory support
• Neuroprotection (investigational)

Contraindications

• Known hypersensitivity to BPC-157 or any component
• Active malignancy or history of cancer (theoretical concern due to angiogenic properties)
• Pregnancy and breastfeeding (no human safety data)
• Pediatric patients (no safety data)

Warnings and Precautions

LIMITED HUMAN DATA: Nearly all safety and efficacy data comes from animal studies, predominantly from a single research group. Only one small pilot study (2 healthy adults, 2025) has evaluated IV BPC-157 in humans, finding it well-tolerated with no adverse effects at doses up to 20 mg.

ANGIOGENESIS CONCERN: BPC-157 promotes angiogenesis (new blood vessel formation), which could theoretically promote tumor growth or worsen existing cancers.

REGULATORY STATUS: The FDA has stated there is insufficient evidence on whether BPC-157 would cause harm to humans. It is not approved for clinical use.

PRODUCT QUALITY: As an unregulated compound, purity, potency, and sterility of commercially available BPC-157 vary significantly between vendors. Use only pharmaceutical-grade products from licensed compounding pharmacies.

NO ESTABLISHED DOSING: No standardized, evidence-based dosing protocols exist for humans.

Common Side Effects

• Injection site reactions (redness, swelling, pain)
• Nausea (mild)
• Dizziness
• Headache
• Fatigue

Serious Adverse Reactions

• No serious adverse reactions have been documented in the limited human studies conducted
• Theoretical risk of promoting tumor growth (angiogenesis)
• Allergic/anaphylactic reactions (possible with any injectable peptide)
• Contamination-related adverse events from non-pharmaceutical-grade products

Drug Interactions

• No formal drug interaction studies have been conducted in humans
• Theoretical interactions with anticoagulants (BPC-157 has been shown to affect platelet function in animal studies)
• May interact with drugs affecting nitric oxide pathways

Special Populations

• Pregnancy/Breastfeeding: Contraindicated due to absence of safety data.
• Cancer Patients: Should not use due to angiogenic properties.
• Pediatric: No safety or efficacy data; not recommended.
• Renal/Hepatic Impairment: No data available.

Generic and Brand Names

• Generic Name: Bremelanotide
• Brand Names: Vyleesi
• Other Designation: PT-141
• Drug Class: Melanocortin receptor agonist (MC4R agonist)
• Route: Subcutaneous injection

FDA-Approved Indications

• Vyleesi: Treatment of acquired, generalized hypoactive sexual desire disorder (HSDD) in premenopausal women as characterized by low sexual desire that causes marked distress or interpersonal difficulty

IMPORTANT LIMITATION: Vyleesi is NOT indicated for:

• Treatment of HSDD in postmenopausal women
• Treatment of HSDD in men (though off-label use for male sexual dysfunction is common in clinical practice)
• Enhancement of sexual performance
• Use on-demand solely for sexual activity (requires pre-planning ~45 minutes prior)

Off-Label Use in Men: Bremelanotide (PT-141) is prescribed off-label by healthcare providers for male sexual dysfunction, including hypoactive sexual desire disorder and erectile dysfunction, particularly when driven by neuropsychological or hormonal causes. This use is not FDA-approved, and providers should counsel patients accordingly.

Contraindications

• Uncontrolled hypertension
• Known cardiovascular disease
• Known hypersensitivity to bremelanotide or any excipient

Warnings and Precautions

BLOOD PRESSURE EFFECTS: Bremelanotide transiently increases systolic and diastolic blood pressure and reduces heart rate after each dose. These changes usually resolve within 12 hours. To minimize blood pressure effects:

• Do NOT administer more than one dose within 24 hours
• Do NOT use more than 8 doses per month
• Blood pressure should be assessed before starting treatment

FOCAL HYPERPIGMENTATION: Reported in approximately 1% of patients receiving up to 8 doses per month. Includes hyperpigmentation of the face, gingiva, and breasts. Risk is higher in:

• Patients with darker skin
• Patients using daily dosing (off-label)
• Resolution after discontinuation is not guaranteed

NAUSEA: The most common side effect. Nausea may be severe and prolonged (lasting 2+ hours), particularly with initial doses. Anti-emetic therapy was needed in 13% of patients; 8% discontinued due to nausea.

EFFECT ON ORAL MEDICATIONS: Bremelanotide may slow gastric motility, potentially reducing the rate and extent of absorption of concomitantly administered oral medications.

Common Side Effects (from Clinical Trials)

• Nausea: 40% (vs. 1% placebo) -- most common; often decreases with subsequent doses
• Flushing: 20% (vs. <1% placebo)
• Injection site reactions: 13%
• Headache: 11% (vs. 8% placebo)
• Vomiting: Reported at significant rates
• Hot flush: Common
• Nasopharyngitis: Common
• Hyperpigmentation: ~1% (with up to 8 doses/month)

Side Effects in Men (Off-Label Use, from Published Studies):

• Nausea: ~30%
• Flushing: ~22%
• Headache: ~13%
• Spontaneous erections (lasting ~24 hours post-injection): ~13%
• Incontinence: ~4%
• Cramping / abdominal burning: ~4% each

Serious Adverse Reactions

• Transient hypertension
• Severe nausea requiring medical intervention
• Hypersensitivity reactions
• Persistent focal hyperpigmentation (may not resolve)
• Cardiovascular events in patients with uncontrolled hypertension or cardiovascular disease

Drug Interactions

• Oral medications: Bremelanotide may reduce the rate and extent of absorption of concomitantly administered oral medications due to slowing of gastric motility. Avoid taking oral medications that require rapid onset within 1-2 hours of bremelanotide administration.
• Naltrexone: Coadministration with naltrexone significantly decreased the exposure of bremelanotide. Avoid concomitant use with naltrexone. Allow a washout period.
• Indomethacin: Minor interaction noted but not clinically significant.
• Blood pressure medications: Consider additive or opposing effects on blood pressure and heart rate.

Special Populations

• Pregnancy: Based on animal studies, bremelanotide may cause fetal harm. In animal reproduction studies, daily administration to pregnant dogs at exposures >= 16 times the maximum recommended dose produced fetal harm. Advise females of reproductive potential to use effective contraception.
• Nursing Mothers: No data on presence in human milk. Consider benefits vs. risks.
• Pediatric: Safety and effectiveness not established.
• Geriatric: Safety and effectiveness not established in geriatric patients.
• Renal Impairment: No dose adjustment needed for mild to moderate renal impairment. Has not been studied in severe renal impairment.
• Hepatic Impairment: Use with caution in severe hepatic impairment (Child-Pugh C). Patients with severe hepatic impairment may have increased incidence and severity of adverse reactions (especially nausea and vomiting).

Administration Notes

• Inject subcutaneously in the abdomen or thigh at least 45 minutes before anticipated sexual activity
• 1.75 mg per dose (single-dose autoinjector)
• Maximum: 1 dose per 24 hours; 8 doses per month
• Rotate injection sites

Generic and Brand Names

• Generic Name: Clomiphene Citrate
• Brand Names: Clomid, Serophene
• Drug Class: Selective Estrogen Receptor Modulator (SERM)
• Route: Oral tablet
• FDA Status: FDA-approved for ovulation induction in women. Off-label use in men for hypogonadism and fertility preservation is well-established in clinical practice.

Primary Indications/Uses

• Ovulation induction in anovulatory women (FDA-approved)
• Male hypogonadotropic hypogonadism (off-label)
• Testosterone optimization in men without suppressing the HPG axis
• Male fertility preservation in patients on or transitioning off TRT

Contraindications

• Pregnancy (Category X) — may cause fetal harm
• Liver disease or history of hepatic dysfunction
• Abnormal uterine bleeding (undiagnosed)
• Ovarian cysts or enlargement not due to PCOS
• Hormone-sensitive tumors (ovarian, uterine, breast, pituitary)
• Known hypersensitivity to clomiphene or any excipient

Warnings and Precautions

VISUAL DISTURBANCES: Blurred vision, scotomata, and photophobia have been reported and may be dose-related. Discontinue immediately if visual symptoms occur and obtain ophthalmologic evaluation before resuming. These effects may be irreversible.

OVARIAN HYPERSTIMULATION: Risk of ovarian enlargement and hyperstimulation syndrome (OHSS), primarily in female patients. Monitor ovarian response.

MULTIPLE GESTATION: Increased incidence of twins and higher-order multiple pregnancies in female patients.

PSYCHIATRIC EFFECTS: Mood changes, irritability, and emotional lability have been reported in both male and female patients.

PSA MONITORING: In men, clomiphene stimulates testosterone production, which may affect PSA levels. Monitor accordingly in men aged 40 or older.

Common Side Effects

• Hot flashes (most common)
• Mood changes, irritability, emotional lability
• Breast discomfort or tenderness
• Headache
• Nausea, bloating, GI discomfort
• Visual blurring or disturbances
• Testicular discomfort (in men)

Serious Adverse Reactions

• Persistent or worsening visual disturbances (potentially irreversible)
• Ovarian hyperstimulation syndrome (females)
• Hepatotoxicity (rare; liver enzyme elevation)
• Thromboembolism (rare, associated with hyperstimulation)
• Seizures (rare)

Drug Interactions

• Estrogen-containing products may counteract clomiphene's receptor competitive mechanism
• Aromatase inhibitors: additive effects on estrogen suppression
• Androgenic steroids: may blunt clomiphene's LH/FSH stimulatory response

Special Populations

• Pregnancy: Absolutely contraindicated.
• Nursing Mothers: Not recommended.
• Pediatric: Not indicated.
• Geriatric: Use with caution; not well established.
• Hepatic Impairment: Contraindicated.

Monitoring Parameters

• Total testosterone, LH, FSH (men)
• Estradiol, ovarian size (women)
• Liver function tests at baseline and periodically
• Visual symptoms at each visit
• PSA (men 40+)

Generic and Brand Names

• Generic Name: Dutasteride
• Brand Names: Avodart (oral capsule); compounded topical formulations available
• Drug Class: Dual 5-Alpha Reductase Inhibitor (Type I and II)
• Route: Oral capsule; compounded topical scalp solution
• FDA Status: FDA-approved (Avodart) for benign prostatic hyperplasia. Topical compounded formulations are not FDA-approved. In 2025, the FDA issued a safety communication regarding compounded topical dutasteride for hair loss.

Primary Indications/Uses

• Benign prostatic hyperplasia (FDA-approved)
• Androgenetic alopecia in men (off-label; more potent than finasteride for DHT suppression)
• Scalp-applied compounded formulation for hair restoration (off-label)

Contraindications

• Women who are pregnant or may become pregnant — dutasteride is teratogenic (Category X); male fetuses may develop genital abnormalities
• Women of childbearing potential should not handle dutasteride capsules or compounded topical formulations
• Known hypersensitivity to dutasteride, other 5-alpha reductase inhibitors, or any component
• Pediatric patients

Warnings and Precautions

HIGH-GRADE PROSTATE CANCER: Dutasteride reduces the incidence of low-grade prostate cancer but has been associated with an increased risk of high-grade prostate cancer (Gleason 8–10) in the REDUCE trial. Discuss risk/benefit with patients.

POST-5ARI SYNDROME: As with finasteride, some men report persistent sexual side effects (low libido, ED, ejaculatory disorders) after discontinuation. The FDA has received reports of persistent adverse events from compounded topical dutasteride including sexual dysfunction, cognitive impairment, and depression.

PSA MONITORING: Dutasteride suppresses serum PSA by approximately 50% within 3–6 months. Adjust PSA interpretation accordingly for prostate cancer screening.

BLOOD DONATION: Do not donate blood while taking dutasteride or for 6 months after stopping (longer half-life than finasteride).

SYSTEMIC ABSORPTION (TOPICAL): Compounded topical scalp formulations can result in measurable systemic DHT suppression. Prescribers should be aware that adverse effects comparable to oral dutasteride may occur with topical use.

Common Side Effects

• Decreased libido
• Erectile dysfunction
• Ejaculatory disorders (decreased volume, retrograde ejaculation)
• Gynecomastia / breast tenderness
• Dizziness
• Scalp irritation or dryness (topical formulations)

Serious Adverse Reactions

• Persistent sexual dysfunction after discontinuation
• Depression, anxiety, cognitive complaints
• High-grade prostate cancer (with long-term use)
• Severe hypersensitivity reactions (angioedema, urticaria)
• Male breast cancer (post-marketing reports)

Drug Interactions

• CYP3A4 inhibitors (ritonavir, ketoconazole, verapamil, diltiazem): may increase dutasteride plasma levels
• Tamsulosin (Jalyn combination): increased exposure to both agents
• Testosterone/androgens: may partially overcome DHT suppression at high doses

Special Populations

• Women: Contraindicated in pregnancy and women who may become pregnant.
• Pediatric: Not indicated.
• Geriatric: No dosage adjustment required.
• Hepatic Impairment: Use with caution; dutasteride is extensively metabolized by the liver. Not studied in severe hepatic impairment.

Monitoring Parameters

• Serum PSA (with interpretation adjusted for 50% reduction)
• Digital rectal exam / prostate evaluation
• Sexual function and mood symptoms
• Liver function tests in patients with hepatic concerns

Generic and Brand Names

• Generic Name: Estradiol (17-beta estradiol)
• Brand Names (topical/transdermal): Divigel, Elestrin, EstroGel, Evamist, Minivelle, Vivelle-Dot; compounded topical creams and gels
• Drug Class: Estrogen; Female Sex Hormone
• Route: Topical gel, cream, patch, or spray; compounded transdermal preparations
• FDA Status: Multiple FDA-approved estradiol topical/transdermal products. Compounded formulations are not FDA-approved.

Primary Indications/Uses

• Moderate-to-severe vasomotor symptoms (hot flashes) associated with menopause
• Moderate-to-severe vulvar and vaginal atrophy associated with menopause
• Female hormone replacement therapy (HRT)
• Prevention of postmenopausal osteoporosis
• Component of gender-affirming hormone therapy (transgender women)

Contraindications

• Undiagnosed abnormal genital or uterine bleeding
• Known, suspected, or history of breast cancer
• Known or suspected estrogen-dependent neoplasia (endometrial cancer, ovarian cancer)
• Active or history of DVT, PE, or arterial thromboembolic disease (stroke, MI)
• Liver dysfunction or disease
• Known hypersensitivity to estradiol or any component
• Pregnancy

Warnings and Precautions

ENDOMETRIAL CANCER: Unopposed estrogen therapy in women with an intact uterus increases the risk of endometrial cancer. Always combine with a progestogen in women with a uterus.

CARDIOVASCULAR RISK: The WHI study reported increased risk of stroke and DVT with combined HRT. Risk must be individualized based on patient age, time since menopause, and cardiovascular risk factors.

BREAST CANCER: Combined estrogen-progestin therapy increases breast cancer risk. Estrogen-only therapy may also increase risk with prolonged use. Annual mammographic surveillance is recommended.

DEMENTIA RISK: The Women's Health Initiative Memory Study (WHIMS) reported increased risk of probable dementia in postmenopausal women 65+ taking combined HRT. Not recommended for dementia prevention.

APPLICATION SITE TRANSFER: Topical estradiol gels and creams can transfer to others through skin contact. Cover application site after gel dries.

Common Side Effects

• Headache
• Breast tenderness or pain
• Nausea
• Application site reactions (redness, irritation)
• Vaginal bleeding or spotting (initial period or breakthrough)
• Bloating, fluid retention
• Mood changes

Serious Adverse Reactions

• Deep vein thrombosis (DVT) / Pulmonary embolism (PE)
• Stroke
• Myocardial infarction (higher risk with combined HRT)
• Breast cancer (with prolonged use)
• Endometrial cancer (unopposed estrogen in patients with uterus)
• Gallbladder disease
• Hypertriglyceridemia

Drug Interactions

• CYP3A4 inducers (rifampin, carbamazepine, St. John's Wort, phenobarbital): reduce estrogen levels and efficacy
• CYP3A4 inhibitors (ketoconazole, erythromycin, grapefruit juice): may increase estradiol levels
• Thyroid hormone: estrogen may increase thyroid-binding globulin, reducing free T4/T3
• Anticoagulants: estrogen may alter coagulation factors; monitor INR with warfarin

Special Populations

• Pregnancy: Contraindicated.
• Nursing Mothers: May reduce lactation; not recommended.
• Pediatric: Not indicated (except under specialist care for delayed puberty or gender-affirming therapy).
• Hepatic Impairment: Contraindicated in active liver disease.

Monitoring Parameters

• Serum estradiol levels
• Annual mammography
• Endometrial thickness / pelvic exam (women with intact uterus)
• Blood pressure
• Triglycerides (especially in patients with hypertriglyceridemia)
• Liver function tests

Generic and Brand Names

• Generic Name: Estriol (E3)
• Brand Names: No FDA-approved standalone estriol product currently marketed in the US. Available through compounding pharmacies, often as Bi-Est or Tri-Est combined formulas.
• Drug Class: Weak Estrogen; Naturally Occurring Estrogenic Hormone
• Route: Compounded topical cream, vaginal cream, or sublingual preparation
• FDA Status: Not FDA-approved as a standalone product. Compounded formulations are not FDA-approved.

Primary Indications/Uses

• Genitourinary syndrome of menopause (vaginal dryness, atrophy, dyspareunia)
• Component of bioidentical hormone replacement therapy (BHRT)
• Recurrent UTI prevention in postmenopausal women (vaginal estriol)
• Skin hydration and anti-aging applications

Contraindications

• Pregnancy
• Known, suspected, or history of estrogen-dependent cancers (breast, endometrial)
• Undiagnosed vaginal bleeding
• Active or history of thromboembolic disease
• Severe hepatic dysfunction
• Hypersensitivity to estriol or any component

Warnings and Precautions

ESTROGEN CLASS EFFECTS: While estriol is a weaker estrogen than estradiol, it shares the class-level risks of all estrogens including endometrial stimulation with prolonged use, thromboembolic events, and breast cancer risk. The magnitude of these risks with compounded estriol is not well characterized due to lack of large clinical trials.

ENDOMETRIAL STIMULATION: Estriol is considered less stimulatory to the endometrium than estradiol, but women with an intact uterus receiving systemic estriol should still be monitored for endometrial thickening.

NOT A RISK-FREE ALTERNATIVE: Estriol is often marketed as "safer" than estradiol, but this has not been proven in clinical trials. Patients should not assume compounded estriol products have fewer risks than FDA-approved estrogen therapy.

VAGINAL ROUTE: Vaginal estriol is largely locally absorbed, but systemic effects can occur with higher doses. Monitor for systemic estrogen effects.

Common Side Effects

• Vaginal discharge (with vaginal application)
• Breast tenderness
• Headache
• Nausea
• Application site irritation
• Spotting or light bleeding

Serious Adverse Reactions

• Thromboembolic events (DVT, PE, stroke) — risk lower than with potent estrogens but not zero
• Endometrial hyperplasia or carcinoma with prolonged use without progestogen
• Breast cancer risk with long-term systemic use

Drug Interactions

• CYP3A4 inducers may reduce estriol efficacy
• Thyroid hormone: estrogen increases thyroid-binding globulin
• Anticoagulants: monitor coagulation status

Special Populations

• Pregnancy: Contraindicated.
• Pediatric: Not indicated.
• Hepatic Impairment: Use with caution; avoid in severe impairment.

Monitoring Parameters

• Serum estradiol/estriol levels
• Endometrial thickness (women with intact uterus on prolonged therapy)
• Breast exam / mammography annually
• Symptoms of thromboembolic events

Generic and Brand Names

• Generic Name: Finasteride
• Brand Names: Propecia (1 mg), Proscar (5 mg)
• Drug Class: 5-Alpha Reductase Inhibitor
• Route: Oral tablet; also available as compounded topical formulation
• FDA Status: FDA-approved (Propecia for male pattern hair loss; Proscar for benign prostatic hyperplasia). The FDA issued a safety alert in 2025 regarding compounded topical finasteride products.

Primary Indications/Uses

• Treatment of male pattern hair loss (androgenetic alopecia) at 1 mg/day
• Treatment of symptomatic benign prostatic hyperplasia (BPH) at 5 mg/day

Contraindications

• Hypersensitivity to finasteride or any component of the formulation
• Women who are pregnant or may become pregnant (Category X) -- finasteride can cause birth defects in male fetuses
• Pediatric patients
• Women of childbearing age should not handle crushed or broken tablets due to risk of absorption through the skin

Warnings and Precautions

PROSTATE CANCER RISK: Finasteride has been associated with an increased rate of high-grade prostate cancer (Gleason score 7-10). Patients should receive risk-versus-benefit counseling.

POST-FINASTERIDE SYNDROME (PFS): Sexual adverse effects (decreased libido, erectile dysfunction, ejaculatory disorders) may persist after discontinuation in some patients. The FDA received 32 adverse event reports (2019-2024) of persistent symptoms from compounded topical finasteride, including erectile dysfunction, anxiety, brain fog, depression, fatigue, insomnia, and testicular pain. Most reports state adverse events continued to persist after product discontinuation.

SUICIDAL IDEATION: In August 2022, the FDA added suicidal ideation and behavior to the adverse reactions listed for finasteride.

PSA LEVELS: Finasteride causes a decrease in serum PSA levels (approximately 50%). This must be accounted for when interpreting PSA results for prostate cancer screening.

MALE BREAST CANCER: Cases of male breast cancer have been reported in post-marketing surveillance.

BLOOD DONATION: Men taking finasteride should not donate blood until at least one month after discontinuation.

Common Side Effects

• Decreased libido
• Erectile dysfunction
• Decreased ejaculate volume
• Dizziness
• Weakness
• Rhinitis
• Skin rash

Serious Adverse Reactions

• Persistent sexual dysfunction after discontinuation (Post-Finasteride Syndrome)
• Depression and suicidal ideation
• High-grade prostate cancer (with long-term 5 mg use)
• Male breast cancer (rare)
• Allergic reactions including angioedema, swelling of lips, tongue, throat, and face

Drug Interactions

• No clinically significant drug-drug interactions have been identified in studies
• Finasteride does not appear to affect the cytochrome P450-linked drug-metabolizing enzyme system

Special Populations

• Women: Absolutely contraindicated in pregnancy and women of childbearing potential. Not indicated for use in women.
• Pediatric: Not indicated for use in children.
• Geriatric: No dosage adjustment necessary; pharmacokinetics not significantly altered.
• Hepatic Impairment: Use with caution; finasteride is metabolized extensively in the liver.

Generic and Brand Names

• Generic Name: GHK-Cu (Glycyl-L-Histidyl-L-Lysine Copper Complex); Copper Peptide
• Brand Names: No FDA-approved brand names. Available as compounded injectable or topical formulations.
• Drug Class: Copper-Binding Tripeptide
• Route: Subcutaneous injection or topical
• FDA Status: NOT FDA-approved for therapeutic use. Available as cosmetic ingredient (topical) and compounded injectable.

Primary Indications/Uses

• Skin rejuvenation and anti-aging
• Wound healing support
• Collagen and elastin stimulation
• Hair growth support
• Anti-inflammatory and antioxidant support

Contraindications

• Known hypersensitivity to GHK-Cu, copper compounds, or any component
• Wilson's Disease or other copper metabolism disorders
• Active skin infections at treatment sites (for topical/injectable)
• Pregnancy and breastfeeding (insufficient data, especially for injectable use)
• Severe allergic reaction to copper compounds

Warnings and Precautions

COPPER TOXICITY (INJECTABLE): Incorrect dosing of injectable GHK-Cu carries a risk of copper toxicity, which in extreme cases requires urgent IV chelation therapy. Long-term injectable use should include periodic monitoring of serum copper and ceruloplasmin levels.

WILSON'S DISEASE: Patients with Wilson's Disease or other copper-handling disorders must consult a specialist before use.

PRODUCT QUALITY: Copper peptide preparations vary significantly in purity, stability, and bioactivity. Use only medical/pharmaceutical-grade formulations from reputable, licensed sources.

TOPICAL PURGING: Topical application may cause temporary "purging" breakouts due to accelerated cell turnover, typically resolving within a few weeks.

COMBINATION PRODUCTS: Avoid combining with harsh exfoliants, strong acids, or other potentially irritating topical agents.

Common Side Effects

• Topical: Mild tingling or burning sensation, localized redness, dryness, peeling, temporary acne purging
• Injectable: Injection site reactions (redness, swelling, tenderness), mild nausea, headache

Serious Adverse Reactions

• Copper toxicity (injectable, with incorrect dosing)
• Severe allergic/anaphylactic reaction
• Systemic copper overload with prolonged high-dose use

Drug Interactions

• No formal drug interaction studies available
• Copper supplements: Use caution to avoid excessive copper intake
• Zinc supplements: High-dose zinc may interfere with copper absorption and vice versa
• Penicillamine and other chelating agents may reduce efficacy

Special Populations

• Pregnancy/Breastfeeding: Avoid, especially injectable forms. Insufficient safety data.
• Wilson's Disease Patients: Contraindicated.
• Renal Impairment: Use with caution; monitor copper levels.
• Pediatric: Safety not established.

Generic and Brand Names

• Generic Name: Glutathione (L-Glutathione, GSH; Gamma-L-Glutamyl-L-Cysteinylglycine)
• Brand Names: No FDA-approved injectable brand names. Available through compounding pharmacies.
• Drug Class: Tripeptide Antioxidant
• Route: Intravenous (IV) push or infusion, intramuscular (IM) injection
• FDA Status: NOT FDA-approved as an injectable therapeutic. No internationally accepted safe dose or frequency for IV glutathione.

Primary Indications/Uses

• Antioxidant and detoxification support
• Skin brightening / lightening (off-label, cosmetic)
• Immune system support
• Liver support and hepatoprotection
• Heavy metal chelation support

Contraindications

• Known hypersensitivity or prior allergic reaction to glutathione
• Asthma (inhaled glutathione can worsen symptoms; IV use with caution)
• Active organ transplant recipients on immunosuppressants (theoretical immune modulation)

Warnings and Precautions

HEPATOTOXICITY: Liver dysfunction has been reported in clinical studies. In one study, 32% of participants receiving 1200 mg IV glutathione twice weekly experienced adverse events, including liver dysfunction.

ANAPHYLAXIS: Cases of anaphylaxis have been reported with IV glutathione.

STEVENS-JOHNSON SYNDROME (SJS) AND TOXIC EPIDERMAL NECROLYSIS (TEN): Severe and potentially fatal skin reactions have been reported.

THYROID AND RENAL DYSFUNCTION: Cases of thyroid dysfunction and renal dysfunction have been reported.

NO STANDARDIZED DOSING: There is no internationally accepted safe dose or frequency for cosmetic or wellness IV glutathione.

STERILITY/ADMINISTRATION: Improper or unsterile IV administration can cause air embolism or sepsis, which can be fatal. Must be administered by qualified medical personnel.

Common Side Effects

• Nausea
• Stomach bloating and gas
• Injection site discomfort, redness, or swelling
• Mild skin rash (usually near injection site)
• Abdominal cramping
• Headache

Serious Adverse Reactions

• Anaphylaxis
• Hepatotoxicity / liver dysfunction
• Stevens-Johnson Syndrome / Toxic Epidermal Necrolysis (rare but potentially fatal)
• Renal dysfunction
• Thyroid dysfunction
• Air embolism (from improper IV technique)
• Sepsis (from unsterile administration)

Drug Interactions

• Chemotherapy drugs: Glutathione may reduce effectiveness of certain chemotherapeutic agents
• Immunosuppressants: Theoretical interaction due to immune modulation
• Antacids: Potential for interaction
• Steroids: May cause adverse reactions when combined
• May increase heart rate in some patients

Special Populations

• Pregnancy/Breastfeeding: Insufficient data; not recommended.
• Cancer Patients: Avoid concurrent use with chemotherapy without oncologist guidance.
• Asthma Patients: Inhaled glutathione is contraindicated; use caution with IV.
• Hepatic/Renal Impairment: Use with caution; monitor function.

Generic and Brand Names

• Generic Name: Chorionic Gonadotropin (HCG)
• Brand Names: Pregnyl, Novarel, Ovidrel (recombinant choriogonadotropin alfa)
• Drug Class: Gonadotropin
• Route: Intramuscular (IM) or subcutaneous injection

FDA-Approved Indications

• Prepubertal cryptorchidism not due to anatomic obstruction
• Hypogonadotropic hypogonadism (selected cases) in males
• Induction of ovulation and pregnancy in anovulatory, infertile women (in conjunction with menotropins)

Note on Off-Label Use in TRT: HCG is commonly used off-label in men receiving testosterone replacement therapy to maintain testicular size, preserve fertility, and support intratesticular testosterone production. While not FDA-approved for this specific indication, its use is well-established in clinical practice.

Contraindications

• Prior hypersensitivity reactions to HCG or any excipient
• Precocious puberty (contraindicated in males with precocious puberty)
• Prostatic carcinoma or other androgen-dependent neoplasm
• Prior allergic reaction to HCG
• Pregnancy (when not used for fertility induction under medical supervision)

Warnings and Precautions

OVARIAN HYPERSTIMULATION SYNDROME (OHSS): (Primarily relevant in female patients) Sudden ovarian enlargement, ascites with or without pain, and/or pleural effusion can occur.

THROMBOEMBOLISM: Arterial and venous thromboembolism have been reported in association with HCG therapy. These events have included cases of pulmonary embolism, stroke, and arterial thromboembolism.

FLUID RETENTION: HCG induces androgen production, which may cause fluid retention. Use with caution in patients with cardiac disease, renal disease, epilepsy, migraine, or asthma.

PRECOCIOUS PUBERTY RISK: In pediatric patients treated for cryptorchidism, HCG may induce precocious puberty. Therapy should be discontinued if signs of precocious puberty occur.

ANTIBODY FORMATION: Patients may develop antibodies to HCG with prolonged use, potentially reducing effectiveness.

Common Side Effects

• Injection site pain, redness, swelling
• Headache
• Irritability and restlessness
• Fatigue
• Depression
• Edema (fluid retention)
• Gynecomastia (in males, due to stimulation of testosterone and estradiol production)
• Mood changes

Serious Adverse Reactions

• Arterial thromboembolism (stroke, MI)
• Venous thromboembolism (DVT, PE)
• Ovarian hyperstimulation syndrome (in females)
• Anaphylaxis and severe hypersensitivity reactions (urinary-derived products)
• Rupture of ovarian cysts (in females)

Drug Interactions

• No known severe or significant drug-drug interactions have been established for HCG.
• Theoretical interaction: HCG stimulates androgen production, so additive effects may occur with exogenous testosterone on hematocrit, estradiol levels, and fluid retention.

Special Populations

• Pregnancy: HCG is used in fertility treatment under medical supervision. However, HCG may cause fetal harm when administered to a pregnant woman outside of directed fertility treatment protocols.
• Nursing Mothers: It is not known whether HCG is excreted in human milk. Exercise caution.
• Pediatric: Used for cryptorchidism. Monitor for precocious puberty.
• Geriatric: Limited data available. Use with appropriate monitoring.
• Renal Impairment: Use with caution due to risk of fluid retention.
• Hepatic Impairment: No specific dosage adjustments established. Use with caution.

Monitoring Parameters (in TRT Context)

• Serum testosterone levels
• Estradiol levels (HCG can increase aromatization)
• Semen analysis (if fertility preservation is the goal)
• Testicular size (ultrasound if indicated)
• Hematocrit
• Symptoms of fluid retention

Generic and Brand Names

• Generic Name: Tri-Immune Boost (Glutathione + Ascorbic Acid/Vitamin C + Zinc Sulfate)
• Brand Names: Tri-Immune Boost; various compounded formulations
• Drug Class: Antioxidant/Vitamin/Mineral Immune Support Combination
• Route: Intramuscular (IM) injection
• FDA Status: NOT FDA-approved as a combination product. Individual components have established safety profiles. Compounded formulation.

Primary Indications/Uses

• Immune system support and optimization
• Antioxidant protection
• Recovery support during illness or stress
• Seasonal immune preparation

Contraindications

• Known allergy to any component (glutathione, ascorbic acid, zinc, or excipients)
• Allergy to corn (some ascorbic acid is corn-derived)
• Kidney disease or renal impairment (risk of oxalate nephropathy from high-dose vitamin C; zinc accumulation)
• Concurrent use of antihypertensive medications (use with caution)
• Pregnancy and breastfeeding

Warnings and Precautions

KIDNEY STONES/RENAL RISK: High-dose vitamin C can increase oxalate excretion, increasing kidney stone risk in susceptible individuals.

ZINC TOXICITY: Excessive zinc intake can cause copper deficiency, neutropenia, and immune dysfunction. Monitor zinc levels with repeated dosing.

GLUTATHIONE CAUTION IN ASTHMA: Glutathione may worsen asthma symptoms in some patients.

IRON ABSORPTION: Vitamin C increases iron absorption, which may be problematic for patients with hemochromatosis or iron overload conditions.

G6PD DEFICIENCY: High-dose IV vitamin C can cause hemolysis in G6PD-deficient patients.

DIABETIC PATIENTS: High-dose vitamin C may interfere with glucose monitoring.

Common Side Effects

• Injection site tenderness, swelling, or bruising
• Temporary fatigue
• Mild flushing or warm sensation
• Nausea
• Metallic taste (zinc)
• Diarrhea (vitamin C, zinc)
• Abdominal cramps

Serious Adverse Reactions

• Allergic reaction/anaphylaxis
• Kidney damage (high-dose vitamin C in renal impairment)
• Stomach ulcers (excessive zinc)
• Hemolysis (high-dose vitamin C in G6PD deficiency)
• Glutathione-related hepatotoxicity (see Glutathione section)

Drug Interactions

• Antihypertensives: Potential interaction
• Iron supplements: Vitamin C increases iron absorption
• Antibiotics (fluoroquinolones, tetracyclines): Zinc may reduce absorption; separate by 2+ hours
• Penicillamine: Zinc reduces absorption
• Diuretics (thiazides, amiloride): May alter zinc levels
• Chemotherapy drugs: Glutathione may interfere with chemotherapy effectiveness
• Anticoagulants: High-dose vitamin C may affect INR

Special Populations

• Pregnancy/Breastfeeding: Not recommended for the combination product.
• Kidney Disease: Use with caution or avoid; vitamin C and zinc may accumulate.
• G6PD Deficiency: Avoid high-dose vitamin C component.
• Hemochromatosis: Vitamin C may worsen iron overload.
• Diabetic Patients: Monitor blood glucose; high-dose vitamin C may interfere with glucometer readings.

Generic and Brand Names

• Generic Name: Ivermectin
• Brand Names: Soolantra (1% cream, FDA-approved for rosacea); compounded topical formulations at varied concentrations
• Drug Class: Macrocyclic Lactone / Antiparasitic; Anti-inflammatory
• Route: Topical cream
• FDA Status: FDA-approved (Soolantra 1% cream) for inflammatory lesions of rosacea. Higher concentration or combination compounded formulations are not FDA-approved.

Primary Indications/Uses

• Inflammatory lesions of rosacea (papules and pustules) — FDA-approved
• Demodex mite infestation (demodicosis)
• Rosacea with suspected Demodex component (off-label/compounded)

Contraindications

• Known hypersensitivity to ivermectin or any component of the formulation
• Not for ophthalmic, oral, or intravaginal use

Warnings and Precautions

FOR TOPICAL USE ONLY: Topical ivermectin (Soolantra / compounded) is distinct from oral ivermectin. Do not ingest. Avoid contact with eyes, mouth, and mucous membranes.

SYSTEMIC ABSORPTION: Systemic absorption from topical application is low but measurable. Risk of systemic adverse effects is low at approved doses but may increase with extensive application over damaged skin.

INFLAMMATORY FLARE: Some patients may experience a temporary worsening of rosacea symptoms during the first weeks of treatment as Demodex die-off occurs.

Common Side Effects

• Skin burning or stinging (most common)
• Dry skin
• Skin discomfort at application site
• Contact dermatitis (rare)

Serious Adverse Reactions

• Systemic hypersensitivity reactions (rare with topical use)
• Severe skin irritation or allergic contact dermatitis

Drug Interactions

• No established clinically significant drug interactions with topical formulations
• Theoretical interaction: CNS depressants (with systemic absorption) — not clinically relevant at topical doses

Special Populations

• Pregnancy: Safety not established; oral ivermectin is Category C. Use topical with caution; minimize exposure over large surface areas.
• Nursing Mothers: Oral ivermectin is excreted in breast milk; topical systemic exposure is low but caution advised.
• Pediatric: Not studied below age 18.
• Geriatric: No dose adjustment required.

Monitoring Parameters

• Rosacea lesion response at 12–16 weeks
• Skin tolerability and application site reactions

Generic and Brand Names

• Generic Name: Levocarnitine (L-Carnitine)
• Brand Names: Carnitor (FDA-approved); compounded injectable formulations
• Drug Class: Amino Acid Derivative / Metabolic Agent
• Route: Intravenous (IV) or intramuscular (IM) injection
• FDA Status: FDA-approved (Carnitor) for primary and secondary carnitine deficiency. Off-label/compounded use for weight management and performance.

Primary Indications/Uses

• Primary systemic carnitine deficiency
• Secondary carnitine deficiency (e.g., hemodialysis patients)
• Fat metabolism support and weight management (off-label)
• Athletic performance and recovery (off-label)
• Mitochondrial function support

Contraindications

• Known hypersensitivity to levocarnitine or any component
• Trimethylaminuria (fish odor syndrome) -- L-carnitine may worsen the condition
• Carnitine palmitoyltransferase II (CPT II) deficiency

Warnings and Precautions

SEIZURE RISK: Seizures have been reported, particularly in patients with a history of seizure disorders. Both patients with and without prior seizure activity have experienced new or worsened seizures.

RENAL IMPAIRMENT: High doses over prolonged periods may result in accumulation of potentially toxic metabolites (trimethylamine and trimethylamine-N-oxide) in patients with severe kidney disease. Monitor renal function.

FISHY ODOR: L-carnitine can cause the urine, breath, and sweat to develop a characteristic "fishy" odor due to trimethylamine production. This is dose-related.

GI TOLERANCE: Oral L-carnitine commonly causes GI side effects; injectable routes may reduce these.

Common Side Effects

• Injection site reaction (38% of patients)
• Diarrhea (35%)
• Headache (37%)
• Abdominal pain (21%)
• Nausea (12%)
• Vomiting (21%)
• Dizziness (18%)
• Body odor / fishy smell
• Muscle weakness (in uremic patients)

Serious Adverse Reactions

• Seizures (new onset or worsening)
• Severe allergic reactions
• Myasthenia (muscle weakness) in uremic patients

Drug Interactions

• Anticonvulsants (carbamazepine, phenobarbital, phenytoin, valproic acid): May decrease blood carnitine levels, especially in children
• Pivalate-conjugated antibiotics: May reduce blood carnitine concentrations
• Anticoagulants (Warfarin): L-carnitine may potentiate anticoagulant effects; monitor INR
• Thyroid hormones: Concurrent use may alter thyroid hormone metabolism
• Valproic acid: May increase carnitine requirements; supplementation often recommended

Special Populations

• Pregnancy: Category B. Use only if clearly needed. No evidence of impaired fertility or fetal harm in animal studies.
• Breastfeeding: Excreted in breast milk; use with caution.
• Renal Impairment: Use with caution; monitor for metabolite accumulation.
• Pediatric: Can be used; monitor carnitine levels in children on anticonvulsants.
• Dialysis Patients: May require supplementation; FDA-approved for this indication.

Generic and Brand Names

• Generic Name: Liothyronine Sodium (T3; Triiodothyronine)
• Brand Names: Cytomel (oral, FDA-approved); compounded topical scalp formulations
• Drug Class: Thyroid Hormone
• Route: Compounded topical (scalp solution); oral tablets available separately
• FDA Status: Oral liothyronine is FDA-approved for hypothyroidism. Compounded topical formulations are not FDA-approved.

Primary Indications/Uses

• Topical scalp application for hair loss associated with thyroid dysfunction or local T3 deficiency
• Used as part of multi-ingredient compounded hair restoration formulas

Contraindications

• Uncorrected adrenal insufficiency (thyroid hormone increases metabolic rate and can precipitate adrenal crisis)
• Acute myocardial infarction
• Thyrotoxicosis
• Hypersensitivity to liothyronine or any component

Warnings and Precautions

SYSTEMIC ABSORPTION: Topical thyroid hormone can be absorbed systemically through the scalp, particularly over inflamed or compromised skin. Systemic T3 elevation can cause tachycardia, arrhythmias, and thyrotoxic symptoms even with topical application.

CARDIOVASCULAR EFFECTS: Even mild excess T3 can increase heart rate, exacerbate angina, and precipitate arrhythmias. Use with caution in patients with coronary artery disease, hypertension, or any cardiac condition.

HYPERTHYROIDISM: Monitor for signs of thyroid hormone excess: palpitations, heat intolerance, weight loss, anxiety, diarrhea, and increased sweating.

OSTEOPOROSIS: Supraphysiologic thyroid hormone levels (even from topical absorption) can accelerate bone loss, particularly in postmenopausal women.

Common Side Effects

• Palpitations or increased heart rate (if systemically absorbed)
• Headache
• Nervousness or anxiety
• Heat intolerance, sweating
• Application site dryness or irritation

Serious Adverse Reactions

• Cardiac arrhythmias (including atrial fibrillation)
• Angina or myocardial infarction (in predisposed patients)
• Thyroid storm (extremely rare with topical use)
• Adrenal crisis (if undiagnosed adrenal insufficiency)
• Accelerated bone loss

Drug Interactions

• Warfarin: thyroid hormone may potentiate anticoagulant effects; monitor INR closely
• Insulin / oral hypoglycemics: thyroid hormone may alter glucose metabolism; adjust diabetes medications
• Beta-blockers: thyroid hormone may reduce the effectiveness of beta-blockers
• Cholestyramine / calcium / antacids: can impair oral thyroid absorption (less relevant for topical use)

Special Populations

• Pregnancy: Thyroid hormone replacement is generally safe in pregnancy; however, compounded topical preparations are unstudied and not recommended during pregnancy.
• Pediatric: Not indicated for topical scalp use.
• Geriatric: Increased sensitivity to thyroid hormone; start with lowest effective dose.
• Cardiac Disease: Use with extreme caution; begin at lower concentrations.

Monitoring Parameters

• TSH, free T3, free T4 levels
• Heart rate and cardiac symptoms
• Weight and metabolic symptoms
• Bone density (long-term use)

Generic and Brand Names

• Generic Name: Methylene Blue (Methylthioninium Chloride)
• Brand Names: ProvayBlue (IV, FDA-approved for methemoglobinemia); various compounded oral/injectable formulations
• Drug Class: Thiazine Dye / Mitochondrial Electron Carrier / Monoamine Oxidase Inhibitor
• Route: Oral, intravenous, or compounded injectable
• FDA Status: FDA-approved ONLY for treatment of acquired methemoglobinemia (IV form). Oral/supplement use for cognitive or mitochondrial support is NOT FDA-approved.

Primary Indications/Uses

• Treatment of methemoglobinemia (FDA-approved, IV)
• Mitochondrial support and cognitive enhancement (off-label)
• Neuroprotection (investigational)
• Antimicrobial (historical)

Contraindications

• G6PD Deficiency (Glucose-6-Phosphate Dehydrogenase Deficiency): MAJOR CONTRAINDICATION. Methylene blue can cause severe hemolytic anemia in G6PD-deficient patients. G6PD testing is recommended before use.
• Concurrent use with serotonergic medications (SSRIs, SNRIs, MAOIs, trazodone, buspirone, meperidine, tramadol) -- RISK OF FATAL SEROTONIN SYNDROME
• Known hypersensitivity to methylene blue or any component
• Severe renal impairment (methylene blue is renally excreted)

Warnings and Precautions

SEROTONIN SYNDROME WARNING: Methylene blue is a potent monoamine oxidase inhibitor. It must NEVER be combined with serotonergic medications including SSRIs (fluoxetine, sertraline, citalopram, etc.), SNRIs (venlafaxine, duloxetine), MAOIs, trazodone, buspirone, meperidine, tramadol, triptans, or St. John's Wort. Serotonin syndrome can cause seizures, hyperthermia, coma, and death.

HEMOLYSIS: Can cause breakdown of red blood cells, especially in G6PD-deficient patients and at high doses.

PRODUCT GRADE: ONLY pharmaceutical/USP-grade methylene blue should be used. Industrial, chemical, or aquarium-grade methylene blue contains heavy metals and impurities and is NOT safe for human use.

URINE/STOOL DISCOLORATION: Causes blue-green discoloration of urine, stool, and potentially skin. This is expected and not harmful but should be communicated to patients.

DOSE-DEPENDENT TOXICITY: At high doses (>7 mg/kg), methylene blue can paradoxically cause or worsen methemoglobinemia.

PHOTOSENSITIVITY: Methylene blue can cause photosensitivity. Avoid excessive sun exposure.

There are 198 known drug interactions with methylene blue (129 major, 67 moderate).

Common Side Effects

• Blue-green discoloration of urine and stool
• Nausea and vomiting
• Dizziness
• Headache
• Abdominal pain
• Sweating
• Skin discoloration (blue tinge)
• Metallic or unpleasant taste

Serious Adverse Reactions

• Serotonin syndrome (when combined with serotonergic drugs) -- potentially fatal
• Hemolytic anemia (especially in G6PD deficiency)
• Methemoglobinemia (paradoxical, at high doses)
• Anaphylaxis
• Seizures
• Cardiac arrhythmias
• Severe skin reactions

Drug Interactions

• SSRIs/SNRIs/MAOIs/Trazodone/Buspirone: CONTRAINDICATED -- serotonin syndrome risk
• Meperidine, Tramadol, Fentanyl: Serotonin syndrome risk
• Triptans: Serotonin syndrome risk
• St. John's Wort, Tryptophan: Serotonin syndrome risk
• Drugs metabolized by CYP enzymes: Methylene blue inhibits multiple CYP enzymes
• Photosensitizing drugs: Additive photosensitivity

Special Populations

• G6PD Deficiency: Absolutely contraindicated. Screen before use.
• Pregnancy: Category X in some references. Not recommended.
• Breastfeeding: Not recommended.
• Renal Impairment: Use with caution; dose adjustment may be needed.
• Elderly: Increased sensitivity; start with lower doses.
• Patients on Antidepressants: Must discontinue serotonergic medications with appropriate washout before starting methylene blue. Consult prescriber.

Generic and Brand Names

• Generic Name: MIC (Methionine, Inositol, Choline) Injection; often combined with Vitamin B12 and other B vitamins
• Brand Names: Lipo-B, Lipo-MIC, various compounded formulations
• Drug Class: Lipotropic Agent / Nutritional Supplement
• Route: Intramuscular (IM) injection
• FDA Status: NOT FDA-approved. Compounded formulations that have not undergone FDA review for safety, quality, or efficacy.

Primary Indications/Uses

• Fat metabolism support and weight management
• Liver support and hepatoprotection
• Energy boost (especially with added B12)
• Body composition optimization as adjunct to diet and exercise

Contraindications

• Known hypersensitivity to any component (methionine, inositol, choline, B12, or excipients)
• Sulfa allergy (potential sensitivity to methionine derivatives)
• Severe liver dysfunction
• Kidney disease or renal insufficiency (amino acid overload risk)
• Active cancer, especially hormone-sensitive types
• Pregnancy and breastfeeding (unless specifically cleared by physician)

Warnings and Precautions

NOT FDA-APPROVED: Compounded products do not undergo FDA's formal review process.

SULFA SENSITIVITY: Patients with sulfa allergy should inform providers due to potential cross-sensitivity with methionine.

INJECTION SITE REACTIONS: A 2021 case report documented severe skin inflammation and hard nodules at injection sites from choline injections.

LIVER MONITORING: While MIC is intended to support liver function, patients with compromised liver function should be monitored.

HOMOCYSTEINE: Methionine is a precursor to homocysteine. Patients with hyperhomocysteinemia should use with caution and ensure adequate B6, B12, and folate intake.

COMBINATION PRODUCTS: Many MIC formulations include additional ingredients (B12, carnitine, chromium). Be aware of all components and their individual safety profiles.

Common Side Effects

• Injection site discomfort, redness, or swelling
• Mild nausea or dizziness
• Diarrhea
• Upset stomach
• Fatigue (transient)

Serious Adverse Reactions

• Allergic reaction (especially in sulfa-sensitive patients)
• Severe injection site inflammation and nodule formation (rare)
• Shortness of breath, hives, or itchiness (seek immediate medical attention)

Drug Interactions

• Metformin: May alter B12 and choline metabolism
• Proton pump inhibitors: May reduce B12 absorption (if B12 is included)
• Anticholinergic drugs: May interact with choline component
• Levodopa: Methionine may interfere with levodopa absorption

Special Populations

• Pregnancy/Breastfeeding: Not recommended. Insufficient safety data for the combination. Unknown if compounds pass into breast milk.
• Liver Disease: Use with caution; lipotropic agents are metabolized in the liver.
• Kidney Disease: Use with caution; amino acid overload risk.
• Sulfa-Allergic Patients: Increased risk of sensitivity to methionine.

Generic and Brand Names

• Generic Name: Minoxidil
• Brand Names: Loniten (FDA-approved oral tablets, 2.5 mg and 10 mg); compounded low-dose oral formulations (0.25–5 mg)
• Drug Class: Vasodilator / Potassium Channel Opener; Hair Loss Treatment
• Route: Oral tablet or compounded oral capsule
• FDA Status: Oral minoxidil is FDA-approved only for severe refractory hypertension. Its use for hair loss is entirely off-label. Compounded low-dose oral formulations are not FDA-approved.

Primary Indications/Uses

• Androgenetic alopecia (male and female pattern hair loss) — off-label
• Alopecia areata — off-label
• Diffuse hair shedding / telogen effluvium — off-label
• Severe refractory hypertension — FDA-approved (not typical use in hair loss context)

Contraindications

• Pheochromocytoma (may stimulate catecholamine release)
• Pulmonary hypertension associated with mitral stenosis
• Acute myocardial infarction
• Hypersensitivity to minoxidil or any component

Warnings and Precautions

CARDIOVASCULAR EFFECTS: Oral minoxidil is a potent vasodilator. Even at low doses used for hair loss (0.25–5 mg), it can cause fluid retention, tachycardia, and orthostatic hypotension. Patients with cardiovascular disease should be closely monitored.

PERICARDIAL EFFUSION: Oral minoxidil at higher doses (used in hypertension) can cause pericardial effusion, which may progress to cardiac tamponade. This risk is substantially lower at low hair loss doses but cannot be entirely excluded.

FLUID RETENTION / EDEMA: Peripheral edema is common, particularly with doses above 2.5 mg. Concomitant diuretic use may be necessary.

HYPERTRICHOSIS: Systemic minoxidil causes hair growth throughout the body (hypertrichosis). This is the mechanism exploited for androgenetic alopecia but may be an unwanted effect on the face, arms, and legs — especially in women.

PREGNANCY: Oral minoxidil is Category C. Potential teratogenic and neonatal cardiovascular effects. Avoid in women who are pregnant or planning to become pregnant.

Common Side Effects

• Hypertrichosis (body/facial hair growth) — most common
• Fluid retention / peripheral edema
• Tachycardia (increased heart rate)
• Headache
• Dizziness / lightheadedness
• Initial shedding phase (first 1–3 months of treatment)

Serious Adverse Reactions

• Pericardial effusion or cardiac tamponade (rare at low doses)
• Pulmonary hypertension
• Severe hypotension
• Angina pectoris (reflex tachycardia may worsen ischemia)
• Severe generalized hypertrichosis

Drug Interactions

• Antihypertensives: additive hypotensive effect; dose adjustment may be required
• Diuretics: used concomitantly for fluid retention management; monitor electrolytes
• Guanethidine: risk of severe orthostatic hypotension
• NSAIDs: may blunt vasodilatory effect and worsen fluid retention

Special Populations

• Pregnancy: Category C — avoid unless benefits clearly outweigh risks. Not recommended for use in hair loss in pregnancy.
• Nursing Mothers: Minoxidil is excreted in breast milk; not recommended during breastfeeding.
• Pediatric: Not studied for hair loss in children.
• Geriatric: Increased sensitivity to cardiovascular effects; start at lowest dose.
• Renal Impairment: Use with caution; minoxidil and its metabolites are renally cleared.

Monitoring Parameters

• Blood pressure (baseline and with dose changes)
• Heart rate and cardiac symptoms
• Signs of fluid retention (weight gain, edema)
• Echocardiogram if pericardial effusion is suspected
• Hair regrowth response (3–6 months)

Generic and Brand Names

• Generic Name: Minoxidil / Tretinoin (compounded topical solution)
• Brand Names: Minoxidil alone: Rogaine, Theroxidil; Tretinoin alone: Retin-A, Tretin-X; Combination: various compounded formulations
• Drug Class: Vasodilator (minoxidil) / Retinoid (tretinoin)
• Route: Topical (scalp)
• FDA Status: Minoxidil topical is FDA-approved OTC for hair loss. Tretinoin is FDA-approved for acne. The combination is a compounded formulation (not FDA-approved as a combination product).

Primary Indications/Uses

• Treatment of androgenetic alopecia (male pattern hair loss)
• Tretinoin enhances percutaneous absorption of minoxidil to improve efficacy, particularly in patients who do not respond to minoxidil alone

Contraindications

• Known hypersensitivity to minoxidil, tretinoin, or any component of the formulation
• Pregnancy and breastfeeding (tretinoin is teratogenic -- Category X)
• Patients under 18 years of age
• Sudden, unexplained, or patchy hair loss
• Hair loss after childbirth
• Active scalp infections, inflammation, or open wounds
• Known cardiovascular disease (especially for oral minoxidil; topical carries lower but non-zero systemic risk)
• Pheochromocytoma

Warnings and Precautions

CARDIOVASCULAR RISK: Tretinoin increases systemic absorption of minoxidil, which may lead to cardiovascular side effects (tachycardia, edema, hypotension, chest pain), especially in patients with pre-existing cardiac conditions or compromised scalp integrity.

PERICARDIAL EFFUSION: Minoxidil has been implicated in causing pericardial effusions, including life-threatening cardiac tamponade, in both topical and oral formulations.

PHOTOSENSITIVITY: Tretinoin increases sun sensitivity. Patients should use sun protection on treated areas.

SCALP IRRITATION: The combination may cause more irritation than either agent alone. Patients using other topical scalp medications should exercise caution.

APPLICATION: For external use only. Avoid eyes, mouth, and mucous membranes. Wash hands after application.

Patients over 50 years of age and those with cardiac, renal, or hepatic disease should be carefully evaluated before use.

Common Side Effects

• Scalp irritation, dryness, redness, and itching
• Scalp flaking or peeling
• Temporary increase in hair shedding (telogen effluvium) in first 2-8 weeks
• Hypertrichosis (unwanted hair growth on face/body)
• Contact dermatitis
• Headache

Serious Adverse Reactions

• Tachycardia, chest pain, or palpitations (if systemically absorbed)
• Significant hypotension or dizziness
• Peripheral edema or fluid retention
• Pericardial effusion (rare with topical use)
• Severe allergic reaction

Drug Interactions

• Topical corticosteroids, topical retinoids, or other irritating topical agents may increase irritation
• Other vasodilators or antihypertensives may have additive hypotensive effects
• Avoid concurrent use with photosensitizing agents
• Guanethidine may cause severe orthostatic hypotension with minoxidil

Special Populations

• Women of Childbearing Potential: Absolutely contraindicated due to tretinoin teratogenicity. Reliable contraception required.
• Breastfeeding: Not recommended; minoxidil is excreted in breast milk.
• Pediatric: Not recommended under 18 years of age.
• Elderly: Assess cardiovascular risk carefully before initiation.

Generic and Brand Names

• Generic Name: Nicotinamide Adenine Dinucleotide (NAD+)
• Brand Names: No FDA-approved brand names. Available through compounding pharmacies as injectable or IV formulation.
• Drug Class: Coenzyme / Metabolic Cofactor
• Route: Intravenous (IV) infusion, intramuscular (IM), or subcutaneous injection
• FDA Status: NOT FDA-approved as an injectable therapeutic. NAD+ supplements fall under lighter regulation than prescription drugs.

Primary Indications/Uses

• Cellular energy and mitochondrial support
• Anti-aging and longevity optimization
• Cognitive function support
• Addiction recovery support (off-label)
• Athletic recovery and performance

Contraindications

• Known hypersensitivity to NAD+ or any component
• Uncontrolled hypertension
• Congestive heart failure (CHF)
• Severe liver disease or hepatic impairment
• Severe kidney disease or renal impairment
• Active cancer or history of cancer (use only with oncologist clearance)
• Cardiovascular disease or bleeding disorders

Warnings and Precautions

INFUSION RATE: Many side effects (nausea, flushing, chest tightness) are directly related to infusion speed. IV infusions should be administered slowly and titrated to patient tolerance.

NIACIN FLUSH: Rapid infusion may convert NAD+ to nicotinic acid, causing prostaglandin-mediated flushing, warmth, and redness.

CANCER CONSIDERATION: Although a direct causal link between NAD+ supplementation and cancer progression has not been proven, experts recommend patients with active cancer or cancer history only use NAD+ therapy with oncologist clearance. NAD+ supports cellular proliferation pathways.

HYDRATION: Patients should be well-hydrated before infusion. Fasting for a few hours beforehand may reduce nausea.

PRODUCT QUALITY: Ensure pharmaceutical-grade NAD+ from licensed compounding pharmacies. Products may contain fillers, inaccurate dosages, or contaminants.

MONITORING: Blood pressure and heart rate should be monitored during IV infusion.

Common Side Effects

• Nausea (most common during infusion)
• Flushing, warmth, and skin redness
• Dizziness and lightheadedness
• Headache
• Chest tightness or pressure (during rapid infusion)
• Fatigue (transient)
• Injection site reactions (bruising, swelling, tenderness)
• Abdominal cramping
• Muscle cramping

Serious Adverse Reactions

• Severe hypotension
• Cardiac arrhythmias (in susceptible individuals)
• Severe allergic/anaphylactic reaction
• Exacerbation of heart failure

Drug Interactions

• No formal drug interaction studies conducted
• Antihypertensives: Additive hypotensive effects possible
• Chemotherapy agents: Theoretical interaction with cellular proliferation pathways
• Alcohol: May reduce efficacy of NAD+ therapy

Special Populations

• Pregnancy/Breastfeeding: Not recommended; insufficient safety data.
• Cardiovascular Disease: Use with extreme caution or avoid.
• Cancer Patients: Only with oncologist approval.
• Renal/Hepatic Impairment: Contraindicated in severe cases.
• Elderly: May benefit but require slower infusion rates and monitoring.

Generic and Brand Names

• Generic Name: Nandrolone Decanoate
• Brand Names: Deca-Durabolin
• Drug Class: Anabolic-Androgenic Steroid (AAS); Schedule III Controlled Substance
• Route: Intramuscular injection (compounded or brand)
• FDA Status: Previously FDA-approved for anemia associated with renal insufficiency and metastatic breast cancer. Most commercial versions have been discontinued in the US; available through compounding pharmacies. The FDA-approved indication does not include performance enhancement or body composition.

Primary Indications/Uses

• Anemia associated with renal insufficiency (FDA-approved, historical)
• Muscle wasting / cachexia associated with HIV/AIDS, cancer, or chronic disease (off-label)
• Osteoporosis in postmenopausal women (off-label)
• Joint pain management and connective tissue support in TRT context (off-label)

Contraindications

• Prostate carcinoma or breast cancer in men
• Carcinoma of the breast in women with hypercalcemia
• Pregnancy (virilization of female fetus)
• Nephrotic syndrome
• Known hypersensitivity to nandrolone or sesame oil (vehicle) or any component

Warnings and Precautions

HEPATOTOXICITY: Injectable nandrolone is less hepatotoxic than 17-alpha alkylated oral anabolic steroids, but liver enzyme elevations can still occur. Monitor liver function, especially with prolonged use.

CARDIOVASCULAR EFFECTS: Anabolic steroids adversely affect lipid profiles (decrease HDL, increase LDL), promote left ventricular hypertrophy, and increase red blood cell mass. These changes raise long-term cardiovascular risk.

HPG AXIS SUPPRESSION: Nandrolone suppresses LH and FSH, leading to testicular atrophy and impaired spermatogenesis. Not suitable as a fertility-sparing androgen therapy.

VIRILIZATION IN WOMEN: Women may experience acne, hirsutism, deepening of the voice, and clitoral enlargement. These changes may be irreversible. Nandrolone is more androgenic than some consider in women at higher doses.

PELIOSIS HEPATIS: Rare but life-threatening blood-filled cysts in the liver have been reported with anabolic steroids.

CONTROLLED SUBSTANCE: Schedule III controlled substance. Prescribing must comply with DEA regulations including patient diagnosis documentation.

Common Side Effects

• Acne
• Injection site pain or inflammation
• Decreased HDL cholesterol
• Libido changes
• Testicular atrophy (men)
• Virilization symptoms (women)
• Water retention / edema
• Mood changes, aggression

Serious Adverse Reactions

• Hepatotoxicity / peliosis hepatis
• Atherosclerosis and cardiovascular events (myocardial infarction, stroke)
• Left ventricular hypertrophy
• Polycythemia / erythrocytosis
• Irreversible virilization in women
• Psychiatric effects (mania, aggression, dependence)
• Cholestatic jaundice

Drug Interactions

• Anticoagulants (warfarin): anabolic steroids potentiate anticoagulant effects; monitor INR closely
• Insulin / oral hypoglycemics: may alter insulin sensitivity; adjust dosing
• Corticosteroids: concurrent use may increase risk of edema
• Cyclosporine: possible altered immunosuppressive levels

Special Populations

• Women: Risk of virilization; use only at lowest effective dose with monitoring.
• Pregnancy: Absolutely contraindicated.
• Pediatric: May cause premature epiphyseal closure and permanent stunting of growth; not recommended in children.
• Hepatic Impairment: Use with caution; monitor liver function.
• Renal Impairment: Use with caution; sodium and water retention may worsen.

Monitoring Parameters

• Liver function tests (ALT, AST, bilirubin)
• Lipid panel (especially HDL)
• Complete blood count / hematocrit (polycythemia)
• Testosterone and LH/FSH (HPG suppression)
• Blood pressure
• Virilization symptoms (women)

Generic and Brand Names

• Generic Name: Oxytocin
• Brand Names: Pitocin (IV/IM, FDA-approved for obstetric use only); compounded intranasal, sublingual, and subcutaneous formulations
• Drug Class: Endogenous Neuropeptide / Uterotonic Agent
• Route: Compounded intranasal spray, sublingual, or subcutaneous injection
• FDA Status: Pitocin is FDA-approved only for obstetric indications (labor induction, control of postpartum bleeding). Compounded oxytocin for sexual wellness, anxiety, or social bonding is not FDA-approved.

Primary Indications/Uses

• Enhancement of sexual arousal and intimacy (off-label)
• Management of anxiety and social functioning in wellness contexts (off-label)
• Compounded combination with PT-141 for sexual enhancement (off-label)
• Autism spectrum disorder social interaction studies (investigational)

Contraindications

• Fetal malpresentation (obstetric context)
• Hypersensitivity to oxytocin or any component of the formulation
• Conditions where uterine contractions are contraindicated (in women; obstetric context)

Warnings and Precautions

NOT FDA-APPROVED FOR WELLNESS INDICATIONS: Compounded intranasal or sublingual oxytocin for sexual wellness is not FDA-approved. Efficacy and safety for these indications have not been established in large clinical trials.

HYPONATREMIA: Oxytocin has antidiuretic effects. High doses or prolonged use — particularly combined with large fluid intake — can cause water retention, hyponatremia, and seizures. Risk is low at typical compounded doses but should be considered in patients with fluid/electrolyte imbalances.

CARDIOVASCULAR EFFECTS: Intravenous oxytocin can cause hypotension and reflex tachycardia. Non-IV routes at low doses carry substantially lower risk, but cardiovascular effects should be monitored.

UTEROTONIC EFFECTS IN PREGNANCY: Oxytocin stimulates uterine contractions. Any oxytocin product should be avoided in pregnancy except under obstetric supervision.

Common Side Effects

• Nasal irritation or congestion (intranasal route)
• Headache
• Flushing
• Nausea
• Mild drowsiness or relaxation

Serious Adverse Reactions

• Hyponatremia and hyponatremic seizures (especially with excessive fluid intake)
• Uterine hyperstimulation / premature labor (in pregnant women)
• Anaphylaxis / hypersensitivity reactions (rare)
• Significant hypotension (primarily with high-dose IV use)

Drug Interactions

• Other uterotonic agents: additive uterotonic effects (obstetric context)
• Prostaglandins: synergistic uterotonic effects
• Vasoconstrictors (vasopressors): oxytocin may cause severe hypertension if combined with vasoconstrictors given shortly before or after
• NSAIDs: may reduce oxytocin's uterotonic effect

Special Populations

• Pregnancy: Compounded intranasal/sublingual oxytocin should not be used during pregnancy except under strict medical supervision.
• Nursing Mothers: Oxytocin is naturally released during breastfeeding; compounded additional oxytocin is not established as safe in lactation.
• Pediatric: Not established for wellness indications.
• Renal / Hepatic Impairment: Use with caution; limited data.

Monitoring Parameters

• Blood pressure and heart rate
• Serum sodium (electrolytes) with prolonged or high-dose use
• Signs of fluid retention
• Uterine activity (women of childbearing potential)

Generic and Brand Names

• Generic Name: Compounded Topical Sexual Enhancement Cream (typical formulations include: Sildenafil 1%, Aminophylline 3%, L-Arginine 6%, Pentoxifylline 5%; some formulations also include ergoloid mesylate and/or testosterone)
• Brand Names: Scream Cream, O-Cream, Arousal Cream; various compounded formulations
• Drug Class: Compounded Topical Vasodilator/Bronchodilator/Phosphodiesterase Inhibitor combination
• Route: Topical (external genital application)
• FDA Status: NOT FDA-approved. This is a compounded product. No FDA-approved product exists for this indication. Topical sildenafil cream (3.6%) demonstrated safety and tolerability in a randomized, placebo-controlled trial (published 2024 in The Journal of Sexual Medicine).

Primary Indications/Uses

• Female sexual arousal disorder (FSAD)
• Enhancement of genital sensitivity and arousal in women
• Increased lubrication during sexual activity
• Improvement of orgasmic response

Contraindications

• Known hypersensitivity to any component (sildenafil, aminophylline, arginine, pentoxifylline, or excipients)
• Concurrent use of nitrates or potent nitric oxide donors: Sildenafil-induced vasodilation combined with nitrates can precipitate severe, life-threatening hypotension
• Active genital herpes (arginine may increase herpes simplex virus replication)
• Active migraine or Raynaud's phenomenon (if formulation contains ergoloid mesylate -- risk of vasospasm)
• Severe hepatic impairment
• Uncontrolled bleeding disorders, peptic ulcer disease, or history of intracerebral hemorrhage
• Arrhythmias, uncontrolled hypertension, or recent myocardial infarction (aminophylline has positive chronotropic effects)
• Hormone-sensitive malignancies (breast, endometrial cancer) if formulation contains testosterone

Warnings and Precautions

NOT FDA-APPROVED: This is a compounded product without FDA review for safety or efficacy.

SYSTEMIC ABSORPTION: While topical application results in approximately 100-fold lower systemic exposure compared to oral sildenafil, systemic side effects are possible.

CARDIOVASCULAR RISK: Patients with cardiovascular disease, hypertension, or those taking antihypertensive medications should be evaluated before use.

AMINOPHYLLINE COMPONENT: Can cause tachycardia and insomnia.

TESTOSTERONE COMPONENT (IF PRESENT): Can cause androgenic effects (acne, facial hair growth, mood changes, voice changes) and is contraindicated in hormone-sensitive cancers.

APPLICATION: For external genital use only. Apply 20-30 minutes before sexual activity. Avoid contact with eyes. Wash hands after application.

PARTNER EXPOSURE: Active ingredients may transfer to sexual partners through contact.

Common Side Effects

• Application site discomfort, tingling, or warmth
• Mild headache
• Local irritation or redness
• Nasal congestion (sildenafil)
• Mild flushing

Serious Adverse Reactions

• Severe hypotension (especially if combined with nitrates or multiple vasodilators)
• Tachycardia or palpitations (aminophylline component)
• Significant allergic reaction
• Priapism of the clitoris (very rare)
• Androgenic effects from testosterone component if present (acne, hirsutism, mood changes)

Drug Interactions

• Nitrates (nitroglycerin, isosorbide dinitrate/mononitrate): CONTRAINDICATED -- risk of severe hypotension
• Alpha-blockers: Additive hypotension
• Other PDE5 inhibitors (tadalafil, vardenafil): Do not combine
• CYP3A4 inhibitors (ketoconazole, ritonavir, erythromycin): May increase systemic sildenafil levels
• CYP3A4 inducers (rifampin, carbamazepine): May decrease sildenafil levels
• Theophylline: Additive effects with aminophylline (both are methylxanthines)
• Antihypertensives: Additive blood pressure lowering
• Anticoagulants: Pentoxifylline may increase bleeding risk
• Herpes antivirals: Arginine component may counteract antiviral effects

Special Populations

• Pregnancy: Not recommended. Sildenafil, aminophylline, and testosterone may pose risks to fetal development.
• Breastfeeding: Not recommended; unknown if components pass into breast milk.
• Cardiovascular Disease: Evaluate thoroughly before prescribing. Contraindicated in recent MI, uncontrolled hypertension, or significant arrhythmias.
• Hepatic Impairment: Severe impairment is a contraindication, especially if testosterone-containing.
• Herpes Patients: Contraindicated due to arginine potentially increasing viral replication.
• Male Partners: Counsel that active ingredients may transfer during intimate contact.

Generic and Brand Names

• Generic Name: Semaglutide
• Brand Names:
• Wegovy (subcutaneous injection, weight management)
• Ozempic (subcutaneous injection, type 2 diabetes)
• Rybelsus (oral tablet, type 2 diabetes)
• Drug Class: Glucagon-like peptide-1 (GLP-1) receptor agonist
• Route: Subcutaneous injection (Wegovy, Ozempic) or oral (Rybelsus)

FDA-Approved Indications

• Wegovy (2.4 mg weekly): Chronic weight management as an adjunct to a reduced-calorie diet and increased physical activity in adults with:
• BMI of 30 kg/m2 or greater (obesity), OR
• BMI of 27 kg/m2 or greater (overweight) with at least one weight-related comorbidity (hypertension, type 2 diabetes, dyslipidemia)
• Also approved for reduction of risk of MACE in adults with established cardiovascular disease and either obesity or overweight
• Ozempic: Adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes; reduction of risk of MACE in adults with type 2 diabetes and established cardiovascular disease

Contraindications

• Personal or family history of medullary thyroid carcinoma (MTC)
• Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)
• Known serious hypersensitivity to semaglutide or any excipient (anaphylaxis and angioedema have been reported)
• Do not use in combination with other semaglutide-containing products or other GLP-1 receptor agonists

Warnings and Precautions

BOXED WARNING -- THYROID C-CELL TUMORS: In rodents, semaglutide caused dose-dependent and treatment-duration-dependent thyroid C-cell tumors (adenomas and carcinomas) at clinically relevant exposures. It is unknown whether semaglutide causes thyroid C-cell tumors, including medullary thyroid carcinoma (MTC), in humans. Semaglutide is contraindicated in patients with a personal or family history of MTC or MEN 2. Counsel patients regarding the potential risk for MTC and symptoms of thyroid tumors (neck mass, dysphagia, dyspnea, persistent hoarseness).

ACUTE PANCREATITIS: Fatal and non-fatal hemorrhagic or necrotizing pancreatitis have been observed. If pancreatitis is suspected, semaglutide should be promptly discontinued. Do not restart if pancreatitis is confirmed.

ACUTE GALLBLADDER DISEASE: Cholelithiasis and cholecystitis have been reported (cholelithiasis in 1.6% vs. 1.1% with placebo). Substantial or rapid weight loss can increase the risk of cholelithiasis.

HYPOGLYCEMIA: When used with insulin secretagogues (e.g., sulfonylureas) or insulin, risk of hypoglycemia is increased. Dose reduction of concomitant insulin or secretagogue may be necessary.

ACUTE KIDNEY INJURY: Reported in patients treated with GLP-1 receptor agonists. Most events occurred in patients who experienced dehydration from GI adverse events (nausea, vomiting, diarrhea). Monitor renal function in patients with renal impairment and in patients reporting severe GI reactions.

DIABETIC RETINOPATHY COMPLICATIONS: Rapid improvement in glucose control has been associated with temporary worsening of diabetic retinopathy. Monitor patients with a history of diabetic retinopathy.

SUICIDAL BEHAVIOR AND IDEATION: Reports have been received for patients on weight management medications. Monitor for emergence or worsening of depression, suicidal thoughts or behavior. Discontinue if these occur.

HEART RATE INCREASE: Mean increases in resting heart rate of 1-4 beats per minute have been observed.

Common Side Effects (Incidence >= 5%)

• Nausea: 44% (vs. 17% placebo)
• Diarrhea: 30% (vs. 16% placebo)
• Vomiting: 25% (vs. 7% placebo)
• Constipation: 24% (vs. 10% placebo)
• Abdominal pain: 20% (vs. 11% placebo)
• Headache: 14% (vs. 12% placebo)
• Fatigue: 11% (vs. 6% placebo)
• Dyspepsia: 9% (vs. 4% placebo)
• Dizziness: 8% (vs. 6% placebo)
• Abdominal distension: 7% (vs. 4% placebo)
• Eructation (belching): 7% (vs. 3% placebo)
• Flatulence: 6% (vs. 3% placebo)
• Gastroenteritis: 6% (vs. 4% placebo)
• Gastroesophageal reflux disease (GERD): 5% (vs. 3% placebo)

Note: Most GI adverse events were non-serious (99.5%), mild-to-moderate (98.1%), and transient, occurring most frequently during dose escalation. Only 4.3% of patients permanently discontinued treatment due to GI events.

Serious Adverse Reactions

• Thyroid C-cell tumors (theoretical risk based on animal data)
• Acute pancreatitis (including hemorrhagic and necrotizing)
• Acute gallbladder disease (cholelithiasis, cholecystitis)
• Acute kidney injury
• Severe hypersensitivity reactions (anaphylaxis, angioedema)
• Diabetic retinopathy complications
• Suicidal ideation and behavior
• Intestinal obstruction (reported post-marketing)

Drug Interactions

• Insulin and insulin secretagogues: Increased risk of hypoglycemia. Consider dose reduction.
• Oral medications: Semaglutide delays gastric emptying and may affect absorption of oral medications. Clinical significance varied by drug in studies, but patients should be monitored when starting semaglutide if taking medications with narrow therapeutic windows.
• Oral contraceptives: Efficacy may be reduced due to delayed gastric emptying with oral semaglutide.
• Warfarin: Monitor INR when initiating or changing semaglutide dose.
• Other GLP-1 receptor agonists: Do not use in combination.

Special Populations

• Pregnancy: Not recommended. Weight loss offers no benefit during pregnancy and may cause fetal harm. Discontinue semaglutide at least 2 months before a planned pregnancy due to long washout period.
• Nursing Mothers: No data on presence in human milk. Consider benefits vs. risks.
• Pediatric: Wegovy is approved for patients aged 12 years and older for weight management.
• Geriatric: No overall differences in safety or efficacy. No dose adjustment needed.
• Renal Impairment: No dose adjustment needed, including ESRD. However, monitor for acute kidney injury, especially during dose escalation with GI side effects.
• Hepatic Impairment: No dose adjustment needed. No clinically relevant changes in pharmacokinetics observed across degrees of hepatic impairment.

Monitoring Parameters

• Body weight
• Blood glucose / HbA1c (diabetic patients)
• Signs and symptoms of pancreatitis
• Renal function (especially with GI adverse events)
• Signs of thyroid tumors
• Heart rate
• Gallbladder-related symptoms
• Mental health status (depression, suicidal ideation)

Generic and Brand Names

• Generic Name: Sermorelin Acetate
• Brand Names: Geref (discontinued by manufacturer -- not for safety/efficacy reasons)
• Drug Class: Growth Hormone-Releasing Hormone (GHRH) Analog / Growth Hormone Secretagogue
• Route: Subcutaneous injection
• FDA Status: Previously FDA-approved (Geref) for diagnosis and treatment of growth hormone deficiency in children. Currently available through compounding pharmacies.

Primary Indications/Uses

• Growth hormone deficiency (original FDA indication)
• Age-related growth hormone decline (off-label/wellness)
• Body composition improvement, lean muscle support
• Improved sleep quality
• Enhanced recovery and tissue repair

Contraindications

• Hypersensitivity to sermorelin acetate or any component (including mannitol)
• Active malignancy -- sermorelin stimulates GH/IGF-1, which promotes cell proliferation and could theoretically accelerate tumor growth
• Pregnancy and breastfeeding (safety not established)
• Untreated hypothyroidism (can jeopardize response to sermorelin; must be corrected before initiation)

Warnings and Precautions

HYPOTHYROIDISM: The incidence of hypothyroidism during sermorelin therapy was 6.5% in clinical studies. Thyroid function should be assessed before initiation and monitored throughout treatment.

CANCER HISTORY: While no clear evidence shows sermorelin causes cancer, clinicians exercise extra caution in patients with a history of malignancy due to GH/IGF-1 proliferative pathways.

ANTIBODY FORMATION: Prolonged use may result in the development of antibodies to sermorelin, which may reduce efficacy.

GLUCOSE METABOLISM: Growth hormone elevation may impair glucose tolerance. Monitor blood glucose in diabetic patients or those at risk for diabetes.

INTRACRANIAL HYPERTENSION: Rare cases of benign intracranial hypertension (pseudotumor cerebri) have been reported with GH-stimulating therapies.

INJECTION TECHNIQUE: Must be administered subcutaneously; proper injection technique and site rotation are important.

Common Side Effects

• Injection site reactions (pain, redness, swelling)
• Headache
• Flushing
• Dizziness
• Nausea
• Joint pain
• Fatigue
• Transient difficulty swallowing or chest tightness at injection site

Serious Adverse Reactions

• Allergic reactions, including anaphylaxis (rare)
• Significant edema or swelling
• Difficulty breathing
• Chest pain
• Blurred vision
• Hypothyroidism

Drug Interactions

• Glucocorticoids (e.g., prednisone): May inhibit the GH response to sermorelin
• Cyclooxygenase inhibitors (aspirin, indomethacin): May reduce sermorelin effectiveness
• Insulin: May affect GH response
• Thyroid-lowering medications (e.g., propylthiouracil): May reduce response
• Muscarinic antagonists (e.g., atropine): May decrease sermorelin response
• Somatostatin or somatostatin-releasing drugs (clonidine, levodopa): May blunt GH response
• Other GH-stimulating peptides: Additive effects; use with caution

Special Populations

• Pregnancy/Breastfeeding: Use only if potential benefit justifies potential risk. Safety not established.
• Pediatric: Originally indicated for GH deficiency in children under supervised care.
• Elderly: May benefit from GH optimization; monitor thyroid and glucose.
• Cancer History: Exercise extreme caution; contraindicated in active malignancy.
• Diabetic Patients: Monitor blood glucose closely.

Generic and Brand Names

• Generic Name: Sildenafil Citrate
• Brand Names: Viagra (erectile dysfunction); Revatio (pulmonary arterial hypertension); compounded sublingual troches and oral formulations
• Drug Class: Phosphodiesterase Type 5 (PDE5) Inhibitor
• Route: Oral tablet; compounded sublingual troche
• FDA Status: FDA-approved (Viagra) for erectile dysfunction in men. FDA-approved (Revatio) for pulmonary arterial hypertension. Compounded sublingual formulations are not FDA-approved.

Primary Indications/Uses

• Erectile dysfunction in men (FDA-approved)
• Pulmonary arterial hypertension (FDA-approved, as Revatio)
• Female sexual arousal disorder (off-label, including as a component of Scream Cream)

Contraindications

• Concurrent use with organic nitrates in any form (nitroglycerin, isosorbide mononitrate, isosorbide dinitrate, amyl nitrite/"poppers") — ABSOLUTELY CONTRAINDICATED; potentially fatal hypotension
• Concurrent use with guanylate cyclase (GC) stimulators (riociguat) — CONTRAINDICATED; additive hypotension
• Known hypersensitivity to sildenafil or any component

Warnings and Precautions

NITRATE INTERACTION: Potentially fatal hypotension with concurrent nitrate use. Confirm no nitrates within 24 hours before administering sildenafil; do not administer nitrates within 24 hours of sildenafil.

CARDIOVASCULAR RISK: Assess whether the patient's cardiovascular status can tolerate the hemodynamic demands of sexual activity. Not recommended within 6 months of MI or stroke, in unstable angina, or in NYHA Class II or higher heart failure.

HYPOTENSION WITH ALPHA-BLOCKERS: Sildenafil augments the blood pressure-lowering effect of alpha-blockers. Use the lowest starting dose and confirm patient is hemodynamically stable on alpha-blocker before initiating.

PRIAPISM: Prolonged erections (>4 hours) and priapism (>6 hours) have been reported. Untreated priapism can result in permanent erectile dysfunction. Patients must seek emergency care for erections lasting more than 4 hours.

VISION LOSS (NAION): Non-arteritic anterior ischemic optic neuropathy (NAION) has been reported rarely. Risk factors: low cup-to-disc ratio, age >50, diabetes, hypertension, hyperlipidemia. Discontinue and seek ophthalmologic evaluation immediately if sudden vision loss occurs.

SUDDEN HEARING LOSS: Cases of sudden hearing loss with tinnitus and dizziness have been reported. Seek immediate medical attention.

Common Side Effects

• Headache (16%)
• Flushing (10%)
• Dyspepsia / upset stomach (7%)
• Nasal congestion (4%)
• Dizziness (2%)
• Visual disturbances — blue-tinged vision (cyanopsia), increased light sensitivity, blurred vision (3%)
• Back pain

Serious Adverse Reactions

• Severe hypotension (especially with nitrates or alpha-blockers)
• Priapism (medical emergency)
• Non-arteritic anterior ischemic optic neuropathy (NAION) / sudden vision loss
• Sudden sensorineural hearing loss
• Serious cardiovascular events in patients with underlying cardiovascular disease

Drug Interactions

• Nitrates (all forms): ABSOLUTELY CONTRAINDICATED — potentially fatal hypotension
• GC stimulators (riociguat): CONTRAINDICATED
• Alpha-blockers (tamsulosin, doxazosin): additive hypotension; patient must be stable on alpha-blocker before adding sildenafil
• CYP3A4 inhibitors (ketoconazole, itraconazole, ritonavir, erythromycin, grapefruit juice): substantially increase sildenafil levels; dose adjustment required
• CYP3A4 inducers (rifampin, carbamazepine, phenytoin, St. John's Wort): reduce sildenafil levels; may reduce efficacy
• Other PDE5 inhibitors: do not use concurrently
• Antihypertensives: additive blood pressure lowering

Special Populations

• Pregnancy: Not indicated for women (Viagra indication).
• Pediatric: Not indicated for erectile dysfunction.
• Geriatric (≥65): Sildenafil plasma levels may be higher due to reduced renal clearance; start at lower dose.
• Renal Impairment (CrCl <30 mL/min or on hemodialysis): Starting dose 25 mg.
• Hepatic Impairment (Child-Pugh A/B): Starting dose 25 mg. Child-Pugh C: Not recommended.

Monitoring Parameters

• Blood pressure (before and during use, especially with concurrent antihypertensives)
• Erection duration (priapism monitoring)
• Visual and auditory symptoms
• Cardiovascular symptoms

Generic and Brand Names

• Generic Name: Somatropin (Recombinant Human Growth Hormone, rhGH)
• Brand Names: Zomacton, Genotropin, Norditropin, Humatrope, Omnitrope, Saizen, Nutropin AQ, Serostim
• Drug Class: Recombinant Human Growth Hormone; Pituitary Hormone Analogue
• Route: Subcutaneous injection; intramuscular injection (some formulations)
• FDA Status: FDA-approved for multiple specific indications (growth hormone deficiency in adults and children, Turner syndrome, Prader-Willi, chronic kidney disease, HIV-related wasting, Noonan syndrome). Anti-aging, body composition, and performance uses are not FDA-approved.

Primary Indications/Uses

• Adult growth hormone deficiency (GHD) — FDA-approved
• Pediatric growth hormone deficiency and short stature — FDA-approved
• HIV-associated wasting / cachexia (Serostim) — FDA-approved
• Short bowel syndrome (Zorbtive) — FDA-approved
• Age-related growth hormone decline / anti-aging (off-label)
• Body composition optimization and muscle preservation (off-label)

Contraindications

• Active malignancy (any current cancer diagnosis) — growth hormone promotes cell proliferation
• Active proliferative or severe non-proliferative diabetic retinopathy
• Prader-Willi syndrome in patients who are severely obese or have severe respiratory impairment (risk of sudden death)
• Acute critical illness due to complications of open heart surgery, abdominal surgery, multiple accidental trauma, or acute respiratory failure
• Known hypersensitivity to somatropin or excipients (including metacresol or glycerin in some formulations)
• Closed epiphyses (pediatric patients in whom bone growth is complete)

Warnings and Precautions

MALIGNANCY / TUMOR GROWTH: Somatropin stimulates IGF-1, which has mitogenic properties. Do not use in patients with active malignancy. Patients with prior history of cancer should be thoroughly evaluated for evidence of recurrence before initiating therapy. Monitor for progression or recurrence of any underlying tumor.

DIABETES AND INSULIN RESISTANCE: Growth hormone is a counter-regulatory hormone to insulin. Somatropin can induce insulin resistance and unmask latent diabetes mellitus. Monitor fasting glucose and HbA1c. Adjust diabetes medications as needed.

INTRACRANIAL HYPERTENSION: Benign intracranial hypertension (pseudotumor cerebri) has been reported, primarily in pediatric patients. Presents with papilledema, visual changes, headache, nausea, and vomiting. Discontinue if confirmed; may restart at lower dose after resolution.

FLUID RETENTION: Edema, arthralgia, and myalgia are common early in treatment due to fluid retention from sodium and water retention. These effects typically resolve with dose adjustment.

SLIPPED CAPITAL FEMORAL EPIPHYSIS: Risk in pediatric patients with rapid growth; not applicable in adult use.

HYPOTHYROIDISM: Somatropin therapy may unmask central hypothyroidism or reduce T4 to T3 conversion. Monitor thyroid function and treat if thyroid hormone deficiency develops.

CARPAL TUNNEL SYNDROME: Fluid retention and soft tissue swelling can compress the median nerve. Dose reduction typically resolves symptoms.

Common Side Effects

• Injection site reactions (pain, bruising, lipoatrophy with repeated injections in same site)
• Fluid retention — peripheral edema, joint stiffness, morning stiffness
• Arthralgia and myalgia
• Headache
• Carpal tunnel syndrome
• Hyperglycemia / elevated fasting glucose
• Fatigue (initial weeks)

Serious Adverse Reactions

• New or recurrent malignancy
• Intracranial hypertension (pseudotumor cerebri)
• Pancreatitis (rare)
• Hypersensitivity reactions including anaphylaxis
• Sudden death in Prader-Willi patients with respiratory compromise
• Type 2 diabetes mellitus (unmasked or worsened)

Drug Interactions

• Glucocorticoids: inhibit the growth-promoting effects of somatropin; high-dose corticosteroids may blunt IGF-1 response
• Insulin / oral hypoglycemics: growth hormone induces insulin resistance; dose adjustments required
• CYP450 substrates (cyclosporine, sex hormones, anticonvulsants): somatropin may alter CYP450 enzyme activity and affect levels of these medications
• Estrogen (oral): oral estrogen reduces IGF-1 response more than transdermal estrogen; transdermal preferred in women on HRT

Special Populations

• Pregnancy: Category B (limited human data); use only if clearly needed. Growth hormone is a normal component of pregnancy physiology.
• Nursing Mothers: Unknown if excreted in breast milk; use with caution.
• Geriatric: Elderly patients may have greater sensitivity to fluid retention and glucose effects; start at lowest dose.
• Diabetic Patients: Monitor closely; insulin dose adjustments will likely be needed.

Monitoring Parameters

• Serum IGF-1 (titrate dose to age/sex-appropriate mid-normal range)
• Fasting glucose and HbA1c
• Thyroid function (free T4, TSH)
• Fundoscopic exam if symptoms of intracranial hypertension develop
• Lipid panel
• Blood pressure
• Signs of tumor progression (in patients with prior malignancy)

Generic and Brand Names

• Generic Name: Tadalafil
• Brand Names: Cialis (ED, BPH), Adcirca (pulmonary arterial hypertension)
• Drug Class: Phosphodiesterase type 5 (PDE5) inhibitor
• Route: Oral

FDA-Approved Indications

• Erectile dysfunction (ED): Treatment of ED (on-demand or daily dosing)
• Benign prostatic hyperplasia (BPH): Treatment of signs and symptoms of BPH
• ED and BPH: Combination treatment
• Pulmonary arterial hypertension (PAH): (as Adcirca) Improvement of exercise ability

Contraindications

• Nitrates: Concomitant use of organic nitrates in any form (nitroglycerin, isosorbide mononitrate, isosorbide dinitrate, amyl nitrite/poppers). Tadalafil potentiates the hypotensive effect of nitrates. This combination can cause severe, potentially fatal hypotension. Allow at least 48 hours after the last tadalafil dose before administering any nitrate.
• Guanylate cyclase (GC) stimulators (e.g., riociguat): Concomitant use is contraindicated. PDE5 inhibitors may potentiate the hypotensive effects of GC stimulators.
• Known hypersensitivity to tadalafil or any component of the formulation.

Warnings and Precautions

CARDIOVASCULAR CONSIDERATIONS: Tadalafil has vasodilatory properties. Before prescribing, consider whether the patient's cardiovascular status can tolerate the cardiac risk of sexual activity. Not recommended in patients with:

• Myocardial infarction within the last 90 days
• Unstable angina or angina occurring during sexual intercourse
• NYHA Class II or greater heart failure in the last 6 months
• Uncontrolled arrhythmias, hypotension (<90/50 mmHg), or uncontrolled hypertension (>170/100 mmHg)
• Stroke within the last 6 months

HYPOTENSION: Tadalafil can augment the blood pressure-lowering effect of alpha-blockers and antihypertensive medications. Avoid use with alpha-blockers unless the patient is stable on alpha-blocker therapy. Starting dose of 2.5 mg once daily is recommended with alpha-blockers.

PRIAPISM: Rare reports of prolonged erections (>4 hours) and priapism (painful erections >6 hours). Patients with conditions predisposing to priapism (sickle cell anemia, multiple myeloma, leukemia) should use tadalafil with caution. Untreated priapism can result in irreversible damage to erectile tissue.

VISION LOSS: Non-arteritic anterior ischemic optic neuropathy (NAION) has been reported rarely. Risk may be increased in patients with anatomical or vascular risk factors (low cup-to-disc ratio, age >50, diabetes, hypertension, coronary artery disease, hyperlipidemia, smoking). Advise patients to discontinue and seek immediate medical attention if sudden vision loss occurs.

SUDDEN HEARING LOSS: Cases of sudden decrease or loss of hearing, sometimes with tinnitus and dizziness, have been reported. Advise patients to seek prompt medical attention if this occurs.

HEPATITIS B REACTIVATION: Has been reported in some patients.

Common Side Effects

• Headache: 11-15%
• Dyspepsia: 8-11%
• Back pain: 5-9% (onset 12-24 hours after dosing, resolves within 48 hours)
• Myalgia: 1-5%
• Nasal congestion: 6-7%
• Flushing: 7-8%
• Pain in extremity: 1-3%
• Dizziness: 1-4%
• Abdominal pain: 3-9%
• Diarrhea: 1-3% (more common in patients >= 65 years)

Serious Adverse Reactions

• Severe hypotension (especially with nitrates)
• Priapism
• Non-arteritic anterior ischemic optic neuropathy (NAION) / sudden vision loss
• Sudden sensorineural hearing loss
• Serious cardiovascular events (in patients with underlying cardiovascular disease)
• Stevens-Johnson syndrome and exfoliative dermatitis (rare)

Drug Interactions

• Nitrates (all forms): CONTRAINDICATED. Life-threatening hypotension. Allow 48 hours after last tadalafil dose before administering nitrates.
• Alpha-blockers (e.g., tamsulosin, doxazosin): Additive hypotensive effect. Patient should be stable on alpha-blocker before starting tadalafil.
• CYP3A4 inhibitors (e.g., ketoconazole, itraconazole, ritonavir, erythromycin, grapefruit juice): Increased tadalafil exposure. Ketoconazole 400 mg daily increased tadalafil AUC by 312%. Dose adjustments may be needed.
• CYP3A4 inducers (e.g., rifampin, carbamazepine, phenytoin, phenobarbital): Decreased tadalafil exposure. May reduce efficacy.
• Other PDE5 inhibitors: Do not use in combination.
• Antihypertensives: Additive blood pressure lowering. Monitor blood pressure.
• Alcohol: Excessive alcohol intake with PDE5 inhibitors may increase the potential for orthostatic hypotension.
• GC stimulators (riociguat): CONTRAINDICATED.

Special Populations

• Pregnancy: Category B. Not indicated for use in women. No adequate studies in pregnant women.
• Nursing Mothers: Not indicated for use in women. Unknown whether tadalafil is excreted in human milk.
• Pediatric: Not indicated for use in pediatric patients. Safety and effectiveness not established.
• Geriatric: No overall differences in safety or efficacy in patients >= 65 years. Diarrhea reported more frequently (2.5%) in elderly patients. Consider greater sensitivity of some older patients.
• Renal Impairment:
• Mild to moderate (CrCl 31-80 mL/min): No starting dose adjustment for on-demand use. For daily use, start 2.5 mg.
• Severe (CrCl <30 mL/min) or ESRD on hemodialysis: Maximum dose 5 mg not more than once every 72 hours (on-demand). For daily use, 2.5 mg may be considered with close monitoring.
• Hepatic Impairment:
• Mild to moderate (Child-Pugh A or B): Should not exceed 10 mg (on-demand). For daily use, use with caution.
• Severe (Child-Pugh C): Not recommended due to insufficient data.

Monitoring Parameters

• Blood pressure (especially with antihypertensives)
• Visual and auditory function
• Erection quality and duration
• Symptoms of priapism

Generic and Brand Names

• Generic Name: TB-500 (synthetic fragment of Thymosin Beta-4)
• Brand Names: No FDA-approved brand names. Available as compounded peptide.
• Drug Class: Synthetic Peptide (cell migration and tissue repair)
• Route: Subcutaneous or intramuscular injection
• FDA Status: NOT FDA-approved for any indication in humans. Prohibited by WADA/USADA in competitive athletics.

Primary Indications/Uses (Investigational)

• Tissue repair and wound healing
• Reduction of inflammation
• Improved flexibility and reduced adhesion formation
• Cardiac tissue repair (investigational)
• Hair regrowth support (investigational)

Contraindications

• Known hypersensitivity to TB-500, Thymosin Beta-4, or any component
• Active malignancy or recent cancer diagnosis (promotes angiogenesis and cell proliferation)
• Pregnancy and breastfeeding (no safety data)
• Pediatric patients (safety not established)

Warnings and Precautions

CANCER RISK: TB-500 promotes angiogenesis and cell proliferation. Patients with a current or recent cancer diagnosis should not use TB-500 until more definitive human data is available.

LIMITED HUMAN CLINICAL DATA: Long-term safety profiles are incompletely understood. Most data is preclinical.

CARDIOVASCULAR EFFECTS: TB-500 promotes vasodilation, which may cause blood pressure decreases, dizziness, lightheadedness, or heart palpitations, especially at higher doses or when combined with other vasodilators.

ANAPHYLAXIS RISK: Patients with history of hypersensitivity reactions should not receive TB-500, as repeated exposure increases anaphylaxis risk. Epinephrine should be readily available.

PRODUCT QUALITY: One of the most significant safety concerns is product purity. Unregulated peptide vendors may produce products with inconsistent dosing, bacterial contamination, or mislabeling. Use only pharmaceutical-grade products from licensed compounding pharmacies.

CYCLING RECOMMENDED: Do not use for more than 3 months without cycling (e.g., 3 months on, 6 weeks off; or 6 weeks on, 6 weeks off).

Common Side Effects

• Injection site reactions (redness, swelling, tenderness, bruising, mild itching, warmth)
• Mild fatigue
• Headache
• Temporary lightheadedness
• Temporary mood changes
• Nausea

Serious Adverse Reactions

• Anaphylaxis (especially with repeated dosing)
• Significant hypotension in susceptible individuals
• Heart palpitations
• Theoretical promotion of tumor growth

Drug Interactions

• No formal drug interaction studies in humans
• Use caution with vasodilators and antihypertensives (additive hypotension)
• Caution with anticoagulants (theoretical bleeding risk)

Special Populations

• Pregnancy/Breastfeeding: Not recommended; no safety data.
• Cancer History: Contraindicated in patients with active or recent cancer.
• Pediatric: Safety not established.
• Cardiovascular Disease: Use with caution; may exacerbate hypotension.

Generic and Brand Names

• Generic Name: Testosterone Cypionate
• Brand Names: Depo-Testosterone, Azmiro (autoinjector)
• Drug Class: Androgen; Schedule III Controlled Substance
• Route: Intramuscular (IM) or subcutaneous injection

FDA-Approved Indications

• Treatment of hypogonadism in males due to conditions associated with a deficiency or absence of endogenous testosterone:
• Primary hypogonadism (congenital or acquired): testicular failure due to conditions such as cryptorchidism, bilateral torsion, orchitis, vanishing testis syndrome, orchiectomy, Klinefelter syndrome, chemotherapy, or toxic damage from alcohol or heavy metals
• Hypogonadotropic hypogonadism (congenital or acquired): idiopathic gonadotropin or LHRH deficiency, or pituitary-hypothalamic injury from tumors, trauma, or radiation

Contraindications

• Men with known or suspected carcinoma of the prostate
• Men with carcinoma of the breast
• Women who are or may become pregnant (testosterone is teratogenic and may cause virilization of the female fetus)
• Known hypersensitivity to testosterone cypionate or any component of the formulation
• Patients with serious cardiac, hepatic, or renal disease

Warnings and Precautions

CARDIOVASCULAR RISK: Testosterone cypionate injection may increase the risk of major adverse cardiovascular events (MACE), including myocardial infarction and stroke. Patients should be informed of this risk when deciding whether to use or continue treatment.

VENOUS THROMBOEMBOLISM (VTE): Deep vein thrombosis (DVT) and pulmonary embolism (PE) have been reported in patients using testosterone products. If a VTE is suspected, testosterone therapy should be discontinued and appropriate workup and management initiated.

POLYCYTHEMIA: Testosterone can increase hematocrit. Hematocrit should be checked prior to initiating therapy and monitored periodically. If hematocrit becomes elevated, therapy should be withheld until hematocrit returns to acceptable levels. An elevated hematocrit increases the risk of thromboembolic events.

PROSTATE EFFECTS: Patients with benign prostatic hyperplasia (BPH) should be monitored for worsening signs and symptoms. Patients should be evaluated for prostate cancer prior to initiating therapy, including PSA monitoring.

HEPATIC EFFECTS: Prolonged use of high doses of androgens has been associated with the development of peliosis hepatis and hepatic neoplasms, including hepatocellular carcinoma.

SLEEP APNEA: Treatment with testosterone may potentiate sleep apnea in some patients, especially those with risk factors such as obesity or chronic lung disease.

BONE MATURATION (Pediatric): In children, androgens may accelerate bone maturation without producing compensatory gain in linear growth, potentially compromising adult stature. Effect on bone maturation should be monitored by assessing bone age of the wrist and hand every six months.

EDEMA: Androgens may promote sodium and water retention. Use with caution in patients with pre-existing cardiac, renal, or hepatic disease. Edema with or without congestive heart failure may be a serious complication.

GYNECOMASTIA: May develop and persist in patients being treated for hypogonadism.

Common Side Effects

• Injection site pain, swelling, or redness
• Acne and oily skin
• Gynecomastia (breast tissue enlargement)
• Increased hematocrit/polycythemia
• Mood changes, including irritability and aggression
• Male pattern hair loss
• Hirsutism (increased body hair)
• Seborrhea
• Fluid retention (sodium, chloride, water, potassium, calcium, phosphates)
• Increased or decreased libido
• Headache
• Elevated blood pressure

Serious Adverse Reactions

• Myocardial infarction and stroke
• Venous thromboembolism (DVT, pulmonary embolism)
• Severe polycythemia
• Liver damage (peliosis hepatis, hepatic neoplasms with prolonged high-dose use)
• Worsening of sleep apnea
• Depression, suicidal ideation (rare)
• Suppression of spermatogenesis leading to azoospermia (potentially reversible upon discontinuation)
• Anaphylaxis (rare)

Drug Interactions

• Oral anticoagulants (e.g., warfarin): Androgens may increase sensitivity to anticoagulants. INR should be monitored and anticoagulant dose may need reduction.
• Insulin and oral hypoglycemics: Androgens may decrease blood glucose and insulin requirements in diabetic patients. Monitor blood glucose closely.
• Corticosteroids: Concurrent use may increase the risk of edema. Use with caution, especially in patients with cardiac or hepatic disease.
• Oxyphenbutazone: Concurrent use may result in elevated serum levels of oxyphenbutazone.

Special Populations

• Pregnancy: Category X. Contraindicated. Testosterone is teratogenic and causes virilization of the female fetus.
• Nursing Mothers: Not recommended. It is not known whether testosterone is excreted in human milk.
• Pediatric: Safety and effectiveness below age 12 have not been established. Risk of accelerated bone maturation and compromised adult stature.
• Geriatric: Elderly patients may be at increased risk for prostatic hyperplasia and prostatic carcinoma. Elderly patients treated with androgens may also be at increased risk of worsening signs and symptoms of BPH.
• Renal Impairment: Use with caution. Edema may be worsened.
• Hepatic Impairment: Use with caution. Hepatotoxicity risk is increased with prolonged use.

Monitoring Parameters

• Serum testosterone levels (trough, before next injection)
• Complete blood count (CBC) with hematocrit (baseline, 3-6 months, then annually)
• Liver function tests
• Lipid panel
• PSA and digital rectal exam (baseline and periodic)
• Bone density (if indicated)
• Signs and symptoms of sleep apnea

Generic and Brand Names

• Generic Name: Testosterone Enanthate
• Brand Names: Delatestryl, Xyosted (FDA-approved); compounded injectable formulations
• Drug Class: Androgen; Schedule III Controlled Substance
• Route: Intramuscular (IM) or subcutaneous (SubQ) injection
• FDA Status: FDA-approved for hypogonadism (primary and hypogonadotropic), delayed puberty in males, and metastatic breast cancer in females. Compounded formulations are not FDA-approved.

Primary Indications/Uses

• Hypogonadism (primary and hypogonadotropic) in men — FDA-approved
• Delayed puberty in males — FDA-approved
• Gender-affirming hormone therapy (testosterone masculinization) in transgender men — off-label
• Male hormone replacement therapy (testosterone enanthate preferred over cypionate by some providers for slightly longer half-life dosing flexibility)

Contraindications

• Carcinoma of the breast or prostate (known or suspected)
• Pregnancy — testosterone causes virilization of female fetus
• Hypersensitivity to testosterone enanthate, sesame oil (vehicle), or any component
• Serious cardiac, hepatic, or renal disease

Warnings and Precautions

POLYCYTHEMIA / ERYTHROCYTOSIS: Testosterone stimulates erythropoiesis. Elevated hematocrit (>54%) increases blood viscosity and thrombotic risk. Monitor CBC; hold or reduce dose if hematocrit exceeds threshold.

CARDIOVASCULAR RISK: TRT may increase risk of major adverse cardiovascular events (MACE), particularly in men with pre-existing cardiovascular disease. Recent evidence (TRAVERSE trial) suggests a modest increase in cardiovascular events in high-risk populations. The FDA requires a cardiovascular risk discussion in prescribing information.

SLEEP APNEA: Testosterone therapy may worsen or unmask obstructive sleep apnea. Screen patients with risk factors (obesity, COPD). Consider sleep study if symptoms develop.

PROSTATE EFFECTS: Testosterone stimulates prostate tissue. May cause or worsen benign prostatic hyperplasia (BPH) symptoms. Monitor PSA and prostate size. Discontinue if prostate cancer is confirmed or suspected.

INFERTILITY / HPG AXIS SUPPRESSION: Exogenous testosterone suppresses LH and FSH, causing testicular atrophy and azoospermia. Patients who desire future fertility should be counseled on sperm banking prior to starting TRT.

VENOUS THROMBOEMBOLISM: Post-marketing reports of serious pulmonary oil microembolism (POME) and anaphylaxis have been associated with injectable testosterone products. Administer slowly and observe patients following each injection.

CONTROLLED SUBSTANCE: Schedule III. Subject to DEA prescribing regulations including triplicate prescriptions in some states.

Common Side Effects

• Injection site pain, bruising, or nodule formation
• Erythrocytosis / elevated hematocrit
• Acne
• Increased libido (especially early in treatment)
• Mood changes (irritability, improved mood, emotional lability)
• Fluid retention / edema
• Testicular atrophy
• Elevated PSA

Serious Adverse Reactions

• Polycythemia / thromboembolic events (DVT, PE, stroke, MI)
• Pulmonary oil microembolism (POME) — immediate injection-associated adverse event
• Prostate carcinoma progression
• Worsening or new sleep apnea
• Hepatotoxicity (rare with parenteral testosterone; more common with oral 17-alpha alkylated androgens)
• Anaphylaxis (rare)

Drug Interactions

• Anticoagulants (warfarin): testosterone may potentiate anticoagulant effect; monitor INR closely
• Insulin / oral hypoglycemics: testosterone improves insulin sensitivity; adjust diabetes medications to avoid hypoglycemia
• Corticosteroids: concurrent use may increase fluid retention and edema
• HCG: may be co-administered to maintain testicular function and intratesticular testosterone

Special Populations

• Women: Testosterone enanthate is indicated for metastatic breast cancer in women (FDA-approved), but use for androgen deficiency in women should be at significantly lower doses with careful monitoring for virilization.
• Pregnancy: Absolutely contraindicated.
• Pediatric: Use only for delayed puberty under specialist supervision; monitor bone age to prevent premature epiphyseal closure.
• Geriatric: Cardiovascular risk may be higher in older men; discuss risk/benefit carefully.
• Hepatic Impairment: Use with caution; testosterone is hepatically metabolized.

Monitoring Parameters

• Serum total testosterone (trough or mid-cycle; target typically 400–800 ng/dL)
• Hematocrit / CBC (every 3–6 months)
• PSA and digital rectal exam (baseline, then per age-appropriate screening guidelines)
• Estradiol (E2) if symptoms of excess aromatization
• LH, FSH (if monitoring HPG suppression or planning fertility restoration)
• Lipid panel
• Blood pressure
• Mood and symptom response

Generic and Brand Names

• Generic Name: Tirzepatide
• Brand Names:
• Mounjaro (type 2 diabetes)
• Zepbound (chronic weight management)
• Drug Class: Dual GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 receptor agonist
• Route: Subcutaneous injection

FDA-Approved Indications

• Mounjaro: Adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes
• Zepbound: Chronic weight management as an adjunct to a reduced-calorie diet and increased physical activity in adults with:
• BMI of 30 kg/m2 or greater (obesity), OR
• BMI of 27 kg/m2 or greater (overweight) with at least one weight-related comorbidity
• Also approved for moderate-to-severe obstructive sleep apnea in adults with obesity

Contraindications

• Personal or family history of medullary thyroid carcinoma (MTC)
• Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)
• Known serious hypersensitivity to tirzepatide or any excipient
• Do not use in combination with other tirzepatide-containing products or any GLP-1 receptor agonist

Warnings and Precautions

BOXED WARNING -- THYROID C-CELL TUMORS: In rats, tirzepatide caused dose-dependent and treatment-duration-dependent thyroid C-cell tumors (adenomas and carcinomas) at clinically relevant exposures. It is unknown whether tirzepatide causes thyroid C-cell tumors, including MTC, in humans. Counsel patients regarding the potential risk and symptoms (neck mass, dysphagia, dyspnea, persistent hoarseness).

ACUTE PANCREATITIS: Has been reported with GLP-1 receptor agonists. If pancreatitis is suspected, promptly discontinue tirzepatide. Do not restart if confirmed.

HYPOGLYCEMIA: Risk increases when used with insulin or insulin secretagogues. Consider dose reduction of concomitant insulin or secretagogue.

ACUTE KIDNEY INJURY: Post-marketing reports in patients treated with GLP-1 receptor agonists and tirzepatide. Majority related to dehydration from GI adverse events. Monitor renal function in patients with renal impairment and those reporting severe GI reactions.

SEVERE GI DISEASE: Use with caution in patients with a history of severe gastrointestinal disease, including severe gastroparesis. Not studied in patients with severe GI disease.

ACUTE GALLBLADDER DISEASE: Cholelithiasis (1.1% vs 1.0% placebo), cholecystitis (0.7% vs 0.2% placebo) reported in clinical trials.

HYPERSENSITIVITY REACTIONS: Serious reactions including anaphylaxis and angioedema have been reported. Discontinue if suspected and treat promptly.

SUICIDAL BEHAVIOR AND IDEATION: Monitor for emergence or worsening of depression, suicidal thoughts or behavior.

Common Side Effects (Incidence >= 5%)

• Nausea: 20-29% (dose-dependent; 5mg: ~24%, 10mg: ~24%, 15mg: ~29%)
• Diarrhea: 16-23% (5mg: ~21%, 10mg: ~20%, 15mg: ~23%)
• Vomiting: 6-13% (dose-dependent)
• Constipation: 6-7%
• Abdominal pain: 5-7%
• Dyspepsia: 5-9%
• Injection site reactions: 3-7%
• Fatigue: 5%
• Hypersensitivity reactions: 3-5%
• Eructation (belching): 3-5%
• Hair loss (alopecia): 4-6%
• Gastroesophageal reflux disease: 3-5%

Note: GI side effects generally occur during dose escalation and decrease over time.

Serious Adverse Reactions

• Thyroid C-cell tumors (theoretical risk based on animal data)
• Acute pancreatitis
• Acute gallbladder disease
• Acute kidney injury
• Severe hypersensitivity/anaphylaxis
• Severe hypoglycemia (when combined with insulin or secretagogues)
• Suicidal ideation and behavior

Drug Interactions

• Insulin and insulin secretagogues: Increased risk of hypoglycemia. Dose reduction may be needed.
• Oral medications: Tirzepatide delays gastric emptying and may affect absorption of oral medications. For patients using oral hormonal contraceptives, switch to a non-oral method or add a barrier method for 4 weeks after initiation and 4 weeks after each dose escalation.
• Other GLP-1 receptor agonists or tirzepatide-containing products: Do not use in combination.
• Other weight management products: Safety and efficacy in combination not established.

Special Populations

• Pregnancy: Not recommended. Weight loss offers no benefit to pregnant females and may cause fetal harm. Based on animal studies, there may be risks to the fetus. Discontinue at least 2 months before planned pregnancy.
• Nursing Mothers: No data available on presence in human milk. Consider benefits vs. risks.
• Pediatric: Safety and effectiveness have not been established in pediatric patients (studies ongoing).
• Geriatric: No overall differences in safety or efficacy. No dose adjustment needed.
• Renal Impairment: No dose adjustment needed, including patients with ESRD. Monitor for acute kidney injury during GI adverse events.
• Hepatic Impairment: No dose adjustment needed based on available data.

Monitoring Parameters

• Body weight
• Blood glucose / HbA1c (diabetic patients)
• Signs and symptoms of pancreatitis
• Renal function
• Signs of thyroid tumors
• Gallbladder-related symptoms
• Mental health status
• Heart rate

Generic and Brand Names

• Generic Name: Trazodone Hydrochloride
• Brand Names: Desyrel, Oleptro (extended-release), Desyrel Dividose, Trittico, Molipaxin
• Drug Class: Serotonin Antagonist and Reuptake Inhibitor (SARI) / Atypical Antidepressant
• Route: Oral
• FDA Status: FDA-approved for treatment of major depressive disorder. Off-label use for insomnia is common.

Primary Indications/Uses

• Major depressive disorder (FDA-approved)
• Insomnia (off-label, widely used)
• Anxiety (off-label)

Contraindications

• Hypersensitivity to trazodone or any component
• Concurrent use with monoamine oxidase inhibitors (MAOIs) or within 14 days of discontinuing an MAOI
• Concurrent use with methylene blue injection (serotonin syndrome risk)
• Concurrent use with linezolid (serotonin syndrome risk)

Warnings and Precautions

BLACK BOX WARNING -- SUICIDALITY: Antidepressants increase the risk of suicidal thinking and behavior in children, adolescents, and young adults (ages 18-24) with major depressive disorder and other psychiatric disorders. Monitor closely for clinical worsening and suicidality, especially during initiation and dose changes.

SEROTONIN SYNDROME: Risk increases when combined with other serotonergic drugs (SSRIs, SNRIs, triptans, tramadol, buspirone, fentanyl, lithium, tryptophan, St. John's Wort). Symptoms include agitation, hallucinations, coma, tachycardia, labile blood pressure, hyperthermia, incoordination, nausea, vomiting, diarrhea. Discontinue immediately if suspected.

PRIAPISM: Trazodone may cause persistent, painful erection lasting >4 hours. Permanent damage to the penis may occur if not treated promptly. Surgical intervention may be required.

QT PROLONGATION: Trazodone therapy is associated with QT prolongation, including torsade de pointes (reported at doses as low as 100 mg with immediate-release formulation). Avoid in patients with pre-existing QT prolongation, recent MI, or uncompensated heart failure.

ORTHOSTATIC HYPOTENSION/SYNCOPE: Risk increased in elderly patients. Dose should be titrated slowly.

BLEEDING RISK: Increased risk when used with aspirin, NSAIDs, or anticoagulants.

ANGLE-CLOSURE GLAUCOMA: May trigger an episode in patients with anatomically narrow angles.

HYPONATREMIA: May occur, especially in elderly patients or those taking diuretics.

Common Side Effects

• Drowsiness/somnolence (most common)
• Dizziness/lightheadedness
• Dry mouth
• Headache
• Nausea/vomiting
• Blurred vision
• Fatigue
• Constipation
• Nasal congestion

Serious Adverse Reactions

• Suicidal ideation and behavior (especially ages <24)
• Serotonin syndrome
• Priapism
• QT prolongation / Torsade de pointes
• Cardiac arrhythmias (PVCs, ventricular tachycardia)
• Seizures
• Orthostatic hypotension / syncope
• Mania/hypomania activation
• Hepatotoxicity (rare)

Drug Interactions

• MAOIs: Contraindicated. Allow 14-day washout period.
• Serotonergic drugs: SSRIs, SNRIs, triptans, buspirone, fentanyl, lithium, tramadol, tryptophan, St. John's Wort -- increased risk of serotonin syndrome
• CYP3A4 inhibitors (ketoconazole, ritonavir, itraconazole): Increase trazodone levels; dose reduction may be needed
• CYP3A4 inducers (carbamazepine, phenytoin): Decrease trazodone levels
• QT-prolonging drugs: Additive risk of arrhythmias
• Anticoagulants/NSAIDs/Aspirin: Increased bleeding risk
• Antihypertensives: Additive hypotension
• Digoxin and Phenytoin: Trazodone may increase serum levels
• CNS depressants/Alcohol: Enhanced sedation
• Methylene blue: Contraindicated (serotonin syndrome risk)

Special Populations

• Pediatric: Not approved for pediatric use. Black Box Warning for increased suicidality.
• Elderly: Start at lower doses. Increased risk of orthostatic hypotension, sedation, and hyponatremia.
• Pregnancy: Category C. Use only if benefit outweighs risk.
• Breastfeeding: Excreted in breast milk. Use with caution.
• Hepatic Impairment: Use with caution; may require dose adjustment.
• Cardiac Disease: Not recommended during initial recovery phase of myocardial infarction. Monitor for arrhythmias.

Generic and Brand Names

• Generic Name: Papaverine / Phentolamine / Alprostadil (compounded combination)
• Common Name: Tri-Mix, TriMix
• Individual Component Brand Names:
• Alprostadil: Caverject, Edex (FDA-approved intracavernosal)
• Papaverine: Generic (not FDA-approved for ED)
• Phentolamine: OraVerse (dental reversal), Regitine (generic; not FDA-approved for ED)
• Drug Class: Combination vasodilator (prostaglandin E1 + non-selective alpha-adrenergic antagonist + smooth muscle relaxant)
• Route: Intracavernosal injection

FDA Approval Status

IMPORTANT NOTE: Tri-Mix as a combination product is NOT FDA-approved. It is a compounded medication prepared by compounding pharmacies. Only alprostadil (alone) is FDA-approved for intracavernosal injection for ED (as Caverject/Edex). The individual components papaverine and phentolamine are not FDA-approved for the treatment of ED. However, Tri-Mix is widely used in clinical practice and is considered standard of care for intracavernosal injection therapy.

Indications (Clinical Use)

• Erectile dysfunction in men who:
• Do not respond adequately to oral PDE5 inhibitors
• Cannot take oral PDE5 inhibitors due to contraindications
• Have severe ED from post-prostatectomy, diabetes, or vascular disease
• Require intracavernosal injection therapy

Standard Formulation

Typical Tri-Mix formulations (concentrations vary by pharmacy):

• Papaverine: 30 mg/mL
• Phentolamine: 1-2 mg/mL
• Alprostadil: 10-40 mcg/mL

Contraindications

• Conditions predisposing to priapism: sickle cell anemia, sickle cell trait, multiple myeloma, leukemia, polycythemia vera, thrombocythemia
• Anatomical deformation of the penis (e.g., angulation, cavernosal fibrosis, Peyronie's disease)
• Penile implants
• Known hypersensitivity to any of the three components
• Patients on monoamine oxidase (MAO) inhibitors (due to phentolamine interactions)
• Patients who should not engage in sexual activity due to cardiovascular risk

Warnings and Precautions

PRIAPISM (MOST CRITICAL WARNING): Prolonged erection lasting 4-6 hours occurred in approximately 4% of patients in alprostadil clinical trials, and priapism (erection >6 hours) occurred in 0.4%. The combination of three vasodilatory agents in Tri-Mix may further increase this risk if improperly dosed. Priapism is a MEDICAL EMERGENCY. If not treated immediately, it can result in permanent damage to the erectile tissue and irreversible erectile dysfunction. Patients must be instructed to seek emergency medical care for any erection lasting more than 4 hours.

PENILE FIBROSIS: Overall incidence in alprostadil clinical studies was 3-8% with prolonged use (up to 18 months). Regular penile examination should be performed to detect fibrosis. Treatment should be discontinued if penile angulation or cavernosal fibrosis develops.

HYPOTENSION: Intracavernosal injection of vasodilatory agents can increase peripheral blood levels, resulting in systemic hypotension, especially at higher doses.

HEMATOMA AND BLEEDING: Injection site hematoma can occur. Risk is increased in patients on anticoagulants.

NEEDLE BREAKAGE: With superfine (29-30 gauge) needles used for injection, needle breakage with retention in the penis has been reported (rare), sometimes requiring surgical removal.

INFECTION: As with any injection, there is a risk of local infection. Proper sterile technique must be used.

Common Side Effects

• Penile pain at injection site: 20-40% (most common; often decreases with continued use)
• Prolonged erection (4-6 hours): ~4%
• Penile fibrosis/Peyronie's-like plaque: 3-8% (with prolonged use)
• Hematoma/ecchymosis at injection site: 3-5%
• Penile edema: 1-3%
• Dizziness/lightheadedness: 1-2% (from systemic hypotension)

Serious Adverse Reactions

• Priapism (erection >6 hours): 0.4% -- medical emergency
• Penile fibrosis/scarring leading to permanent penile deformity
• Severe hypotension (especially with excessive dosing)
• Needle breakage with penile retention (rare)
• Infection/abscess at injection site (rare)

Drug Interactions

• PDE5 inhibitors (tadalafil, sildenafil, vardenafil): Do NOT use Tri-Mix within 24 hours (or 48 hours for tadalafil) of taking a PDE5 inhibitor. Combined use significantly increases risk of prolonged erection, priapism, and hypotension.
• Antihypertensives: Additive hypotensive effect. Monitor blood pressure.
• Anticoagulants (warfarin, heparin, direct oral anticoagulants): Increased risk of injection site bleeding and hematoma.
• MAO inhibitors: Contraindicated with phentolamine component due to risk of severe hypotension.
• Nitrates: Use with extreme caution. Additive vasodilation and hypotension risk.
• Alpha-adrenergic blockers: Enhanced hypotensive effect with phentolamine component.

Special Populations

• Pregnancy: Not applicable (medication for male use only). Female partners should be informed that semen may contain trace amounts of alprostadil.
• Pediatric: Not indicated for use in pediatric patients.
• Geriatric: Elderly patients may be more sensitive to hypotensive effects. Start with the lowest dose and titrate carefully.
• Renal Impairment: Use with caution. May have enhanced sensitivity to vasodilatory effects.
• Hepatic Impairment: Use with caution. Papaverine is hepatically metabolized. Liver function should be monitored with prolonged use.
• Cardiovascular Disease: Assess cardiovascular fitness for sexual activity before prescribing.

Administration and Patient Counseling

• First injection MUST be administered under medical supervision (in-office) to establish safe dose and verify technique
• Injection site should be alternated between sides of the penis and varied along the shaft
• Maximum injection frequency: No more than 3 times per week, with at least 24 hours between injections
• Patients must be trained on proper injection technique, sterile handling, and emergency recognition
• Tri-Mix must be stored frozen and thawed before use (formulation-dependent)

Generic and Brand Names

• Generic Name: Vardenafil Hydrochloride
• Brand Names: Levitra (oral tablet, FDA-approved); Staxyn (orally disintegrating tablet, FDA-approved); compounded sublingual troches
• Drug Class: Phosphodiesterase Type 5 (PDE5) Inhibitor
• Route: Oral tablet; orally disintegrating tablet; compounded sublingual troche
• FDA Status: FDA-approved (Levitra, Staxyn) for erectile dysfunction in men. Compounded sublingual troche formulations are not FDA-approved.

Primary Indications/Uses

• Erectile dysfunction in men — FDA-approved
• Premature ejaculation (off-label)

Contraindications

• Concurrent use with organic nitrates in any form (nitroglycerin, isosorbide mononitrate, isosorbide dinitrate, amyl nitrite/"poppers") — ABSOLUTELY CONTRAINDICATED; potentially fatal hypotension
• Concurrent use with guanylate cyclase (GC) stimulators (riociguat) — CONTRAINDICATED; additive hypotension
• QT prolongation syndromes (congenital or drug-induced) — vardenafil prolongs the QT interval and is contraindicated with Class Ia (quinidine, procainamide) and Class III (amiodarone, sotalol) antiarrhythmics
• Hypersensitivity to vardenafil or any component

Warnings and Precautions

NITRATE INTERACTION: Potentially fatal hypotension with concurrent nitrate use. Vardenafil must not be administered within 24 hours of any nitrate preparation. Confirm no recent nitrate use before prescribing.

QT PROLONGATION: Vardenafil prolongs the QT interval dose-dependently. Avoid in patients with known QT prolongation, hypokalemia, hypomagnesemia, bradycardia, or those taking Class Ia/III antiarrhythmics. Use with caution in patients with heart failure or cardiac abnormalities that may predispose to QT prolongation.

CARDIOVASCULAR RISK: Assess cardiovascular status before prescribing — the hemodynamic demands of sexual activity may be contraindicated in patients with severe cardiovascular disease. Not recommended within 6 months of MI or stroke, in unstable angina, or in NYHA Class II or higher heart failure.

PRIAPISM: Rare reports of prolonged erections (>4 hours) and priapism (>6 hours). Untreated priapism can cause permanent erectile dysfunction. Patients must seek emergency care for erections lasting more than 4 hours.

VISION AND HEARING: NAION (non-arteritic anterior ischemic optic neuropathy) and sudden hearing loss have been reported with PDE5 inhibitors. Discontinue and seek immediate care if sudden vision or hearing changes occur.

ALPHA-BLOCKER INTERACTION: Vardenafil and alpha-blockers both lower blood pressure. Concurrent use may cause significant hypotension. Patients must be hemodynamically stable on alpha-blocker therapy before initiating vardenafil; use lowest starting dose.

Common Side Effects

• Headache (15%)
• Flushing (11%)
• Rhinitis / nasal congestion (9%)
• Dyspepsia (4%)
• Sinusitis (3%)
• Back pain (2%)
• Dizziness (2%)

Serious Adverse Reactions

• Severe hypotension (especially with nitrates or alpha-blockers)
• Cardiac arrhythmias / QT prolongation / torsades de pointes
• Priapism (medical emergency)
• Non-arteritic anterior ischemic optic neuropathy (NAION)
• Sudden sensorineural hearing loss

Drug Interactions

• Nitrates (all forms): ABSOLUTELY CONTRAINDICATED — potentially fatal hypotension
• GC stimulators (riociguat): CONTRAINDICATED
• Class Ia/III antiarrhythmics (quinidine, procainamide, amiodarone, sotalol): CONTRAINDICATED — additive QT prolongation
• Alpha-blockers (tamsulosin, doxazosin, alfuzosin): significant hypotension; patient must be stable before initiating vardenafil
• CYP3A4 inhibitors (ketoconazole, itraconazole, ritonavir, erythromycin, clarithromycin, grapefruit juice): substantially increase vardenafil levels; dose reduction required
• CYP3A4 inducers (rifampin): reduce vardenafil levels; may reduce efficacy
• Other PDE5 inhibitors: do not use concurrently

Special Populations

• Geriatric (≥65): Plasma levels approximately 52% higher; use caution and consider starting at 5 mg dose.
• Hepatic Impairment (Child-Pugh B): Starting dose 5 mg; maximum 10 mg. Child-Pugh C: not recommended.
• Renal Impairment: No dose adjustment needed for mild-moderate impairment; caution with severe renal impairment.
• Pregnancy: Not indicated.
• Pediatric: Not indicated.

Monitoring Parameters

• Blood pressure (before and during use, especially with concurrent antihypertensives)
• ECG if QT prolongation risk exists
• Erection duration (priapism monitoring)
• Visual and auditory symptoms
• Cardiovascular symptoms

Generic and Brand Names

• Generic Name: Methylcobalamin (Vitamin B12)
• Brand Names: Mecobalamin; also available as Cyanocobalamin (Nascobal, Cyanoject) and Hydroxocobalamin
• Drug Class: Water-Soluble Vitamin / Coenzyme
• Route: Intramuscular (IM) or subcutaneous injection
• FDA Status: Cyanocobalamin injection is FDA-approved. Methylcobalamin injectable is available through compounding pharmacies.

Primary Indications/Uses

• Vitamin B12 deficiency
• Pernicious anemia
• Neuropathy and nerve support
• Energy and metabolism support
• Methylation support (methylcobalamin specifically)

Contraindications

• Known hypersensitivity to vitamin B12, cobalt, or any component of the formulation
• Leber's hereditary optic neuropathy (cyanocobalamin specifically, as it can worsen optic atrophy)

Warnings and Precautions

ANAPHYLAXIS: Although rare, allergic reactions including life-threatening anaphylaxis can occur with injectable B12. Hydroxocobalamin tends to be more allergenic than cyanocobalamin. Have epinephrine available.

HYPOKALEMIA: Correction of megaloblastic anemia with B12 may result in fatal hypokalemia due to increased potassium uptake by newly forming red blood cells. Monitor potassium levels, especially in the early phase of treatment for severe deficiency.

POLYCYTHEMIA: B12 therapy can cause polycythemia vera to unmask or worsen. Monitor CBC.

ACNE: High doses (>5-10 mg/week) or prolonged use have been associated with worsening acne, particularly in females.

MASKING OF FOLATE DEFICIENCY: B12 supplementation may mask symptoms of folate deficiency while allowing neurological damage to progress.

GOUT: Treatment of B12 deficiency may precipitate gout due to increased nucleic acid metabolism.

Common Side Effects

• Injection site pain, redness, swelling, or bruising
• Mild diarrhea
• Nausea
• Headache
• Tingling sensation in hands or feet
• Itching or rash

Serious Adverse Reactions

• Anaphylaxis (rare)
• Hypokalemia (during initial treatment of severe deficiency)
• Polycythemia
• Pulmonary edema and congestive heart failure (rare, during aggressive repletion)
• Vascular thrombosis (rare)

Drug Interactions

• Chloramphenicol: May decrease B12 hematologic response
• Colchicine: May impair B12 absorption
• Metformin: Reduces B12 absorption; patients on long-term metformin should monitor B12 levels
• Proton pump inhibitors and H2 blockers (omeprazole, lansoprazole, ranitidine): Reduce B12 absorption
• Aminosalicylic acid: May reduce B12 absorption
• Anticoagulants: Injectable cobalamin may increase bleeding risk
• Heavy alcohol use: Impairs B12 absorption

Special Populations

• Pregnancy: Generally considered safe at recommended doses.
• Breastfeeding: B12 is excreted in breast milk; generally considered safe.
• Renal Impairment: Use with caution; aluminum-containing formulations should be avoided.
• Elderly: Higher prevalence of B12 deficiency; may require ongoing supplementation.
• Vegans/Vegetarians: At increased risk of deficiency; supplementation often recommended.

Generic and Brand Names

• Generic Name: Zolpidem Tartrate
• Brand Names: Ambien (immediate-release); Ambien CR (extended-release); Edluar (sublingual); Zolpimist (oral spray); Intermezzo (sublingual, for middle-of-night waking); compounded preparations
• Drug Class: Nonbenzodiazepine GABA-A Receptor Agonist (Z-drug); Schedule IV Controlled Substance
• Route: Oral tablet; oral spray; sublingual tablet; compounded formulations
• FDA Status: FDA-approved for short-term treatment of insomnia characterized by difficulty with sleep onset (IR) and sleep maintenance (CR). Compounded formulations are not FDA-approved.

Primary Indications/Uses

• Insomnia characterized by difficulty falling asleep (immediate-release) — FDA-approved
• Insomnia with sleep maintenance difficulty (extended-release) — FDA-approved
• Short-term sleep induction; not intended for long-term nightly use

Contraindications

• Known hypersensitivity to zolpidem or any component of the formulation
• Prior complex sleep behaviors (sleep-driving, sleep-eating, etc.) while taking zolpidem or any sedative-hypnotic — these behaviors may be life-threatening

Warnings and Precautions

COMPLEX SLEEP BEHAVIORS (FDA BLACK BOX WARNING): Serious and potentially fatal behaviors including sleep-walking, sleep-driving, and other complex behaviors have been reported with sedative-hypnotics including zolpidem. These can occur with or without memory of the event. Discontinue immediately if complex sleep behaviors occur. Do not take with alcohol or other CNS depressants that increase this risk.

NEXT-DAY IMPAIRMENT: Residual sedation the morning after use impairs driving, operating machinery, and other tasks requiring alertness. Risk is higher with extended-release formulations, in women (lower clearance), and in elderly patients. The FDA recommends not driving the day after taking Ambien CR.

CNS DEPRESSION: Zolpidem causes dose-dependent CNS depression. Concurrent use with alcohol, opioids, benzodiazepines, or other CNS depressants significantly increases the risk of respiratory depression and death.

RESPIRATORY DEPRESSION: In patients with compromised respiratory function (sleep apnea, COPD, obesity hypoventilation), zolpidem may worsen respiratory depression. Avoid or use with extreme caution in these patients.

DEPENDENCE AND WITHDRAWAL: Physical and psychological dependence can develop with prolonged use. Abrupt discontinuation after chronic use can cause rebound insomnia, anxiety, tremors, and withdrawal seizures. Taper dose gradually on discontinuation.

REBOUND INSOMNIA: Transient worsening of insomnia may occur for 1–2 nights after stopping zolpidem. Inform patients so they do not abruptly restart higher doses.

Common Side Effects

• Drowsiness / somnolence (next-day residual sedation)
• Dizziness
• Headache
• Nausea
• Diarrhea
• Anterograde amnesia (memory impairment for events after taking dose)
• Hallucinations (visual or auditory) — particularly in elderly

Serious Adverse Reactions

• Complex sleep behaviors (sleep-driving, sleep-walking, sleep-eating) — potentially fatal
• Severe respiratory depression (especially with concurrent CNS depressants)
• Anaphylaxis and angioedema (rare; discontinue immediately)
• Suicidal ideation and behavior (post-marketing reports with sedative-hypnotics)
• Withdrawal seizures (with abrupt discontinuation after chronic use)

Drug Interactions

• Alcohol: AVOID — synergistic CNS and respiratory depression; dramatically increases risk of complex sleep behaviors
• Opioids: additive respiratory depression; combination carries risk of death
• Benzodiazepines: additive CNS depression
• CYP3A4 inhibitors (ketoconazole, fluconazole, clarithromycin, erythromycin): increase zolpidem plasma levels; reduce dose
• CYP3A4 inducers (rifampin, St. John's Wort): reduce zolpidem levels and efficacy
• Antidepressants (SSRIs, SNRIs, TCAs): additive CNS effects
• Antihistamines, muscle relaxants, anti-anxiety medications: additive sedation

Special Populations

• Women: Zolpidem clearance is slower in women; the FDA recommends a lower starting dose (5 mg IR; 6.25 mg CR) vs. men (10 mg IR; 12.5 mg CR) to reduce next-day impairment.
• Geriatric: Increased sensitivity to sedative effects; higher risk of falls and cognitive impairment. Start at lowest dose (5 mg). Avoid routine nightly use in elderly (Beers Criteria).
• Pregnancy: Category C — limited data; neonates born to mothers using sedative-hypnotics near delivery may experience respiratory depression and withdrawal. Avoid if possible.
• Hepatic Impairment: Significantly reduced clearance; start at 5 mg dose in all patients with hepatic impairment.
• Sleep Apnea: Avoid or use with extreme caution; respiratory depression risk.

Monitoring Parameters

• Sleep quality and duration response
• Next-day sedation and driving ability
• Signs of complex sleep behaviors
• Signs of dependence or misuse
• Respiratory status (patients with sleep apnea or COPD)
• Fall risk assessment in elderly patients

Allergic Reactions

All medications carry a risk of allergic reactions, including anaphylaxis. Patients should be advised to seek immediate medical attention if they experience difficulty breathing, swelling of the face/lips/tongue/throat, severe rash, or hives after taking any medication.

Off-Label Use Disclosure

Some medications may be prescribed for uses not specifically approved by the FDA ("off-label" use). Off-label prescribing is legal and common in medical practice when supported by clinical evidence. Patients will be informed when a medication is being used off-label and counseled on the available evidence, risks, and benefits.

Compounded Medications

Some medications dispensed through this practice may be compounded by a licensed compounding pharmacy. Compounded medications are not FDA-approved products but are prepared in accordance with applicable state and federal pharmacy regulations.

Injectable Products -- General Safety

All injections must be prepared and administered using aseptic technique to prevent infection. Injectable products should be administered by or under the supervision of a licensed healthcare provider. Epinephrine and resuscitation equipment should be immediately available during any injection administration. Many injectable products listed above are compounded formulations that have NOT undergone FDA review for safety, quality, or efficacy -- use only products from licensed, accredited compounding pharmacies (e.g., PCAB-accredited). All injectable products should be stored according to manufacturer/compounder specifications, and many require refrigeration. Patients must disclose ALL medications, supplements, and over-the-counter products to their provider before starting any new treatment.

Adverse Event Reporting

Healthcare providers should report serious adverse events to the FDA MedWatch program (1-800-FDA-1088 or www.fda.gov/medwatch).

Telehealth Practice Notice

This telehealth practice provides medical consultations and prescriptions remotely. Patients are responsible for disclosing their complete medical history, current medications, and any changes in health status. In-person follow-up or emergency care should be sought as directed by the provider.

Testosterone Cypionate

• FDA Prescribing Information -- Depo-Testosterone
• FDA Prescribing Information -- Azmiro (2025)
• Testosterone Cypionate -- Drugs.com Professional
• Testosterone Cypionate -- Mayo Clinic

HCG / Chorionic Gonadotropin

• FDA Prescribing Information -- Pregnyl (2023)
• HCG Injection -- Cleveland Clinic
• HCG in Male Hypogonadism -- PMC

Semaglutide

• FDA Prescribing Information -- Wegovy (2025)
• FDA Prescribing Information -- Ozempic (2023)
• Wegovy Side Effects -- Official Site
• Semaglutide -- StatPearls / NCBI

Tirzepatide

• FDA Prescribing Information -- Zepbound (2024)
• FDA Prescribing Information -- Mounjaro (2025)
• Tirzepatide -- Mayo Clinic
• Tirzepatide GI Side Effects Meta-Analysis -- PMC

Tadalafil

• FDA Prescribing Information -- Cialis (2018)
• Tadalafil -- StatPearls / NCBI
• Questions and Answers for Cialis -- FDA
• Tadalafil Clinical Evidence -- PMC

Tri-Mix (Alprostadil / Papaverine / Phentolamine)

• FDA Prescribing Information -- Caverject / Alprostadil (2017)
• Alprostadil -- StatPearls / NCBI
• Penile Injection Therapy -- Memorial Sloan Kettering
• Intracavernosal Injections for ED -- Fagron Academy

Bremelanotide / PT-141

• FDA Prescribing Information -- Vyleesi (2019)
• Bremelanotide -- Mayo Clinic
• Bremelanotide Safety Profile -- PubMed
• Bremelanotide in Men with Sexual Dysfunction -- Oxford Academic

Finasteride

• FDA Prescribing Information -- Propecia (2022)
• Finasteride -- StatPearls / NCBI
• Finasteride -- Mayo Clinic
• FDA Alert on Compounded Topical Finasteride
• Finasteride Interactions -- Invigor Medical

Minoxidil / Tretinoin Topical

• Minoxidil Topical -- Mayo Clinic
• Minoxidil -- StatPearls / NCBI
• Tretinoin -- StatPearls / NCBI
• Minoxidil + Tretinoin Efficacy Study -- PubMed

Trazodone

• FDA Prescribing Information -- Trazodone (2017)
• Trazodone -- StatPearls / NCBI
• Trazodone -- Mayo Clinic
• Trazodone -- Drugs.com
• Trazodone -- MedlinePlus

BPC-157 Peptide

• BPC-157 in Orthopaedic Sports Medicine -- PMC
• BPC-157 Regeneration or Risk -- PMC
• Safety of IV BPC-157 in Humans -- PubMed
• BPC-157 -- USADA
• BPC-157 -- Examine.com

TB-500 / Thymosin Beta-4

• TB-500 Risks -- OrthoAndWellness
• TB4 and TB-500 Peptide Therapy -- Innerbody
• TB-500 Side Effects -- Swolverine
• Thymosin Beta-4 Clinical Trial -- ClinicalTrials.gov

Sermorelin

• Sermorelin -- Mayo Clinic
• Sermorelin Acetate -- Drugs.com
• Sermorelin -- RxList
• Sermorelin Side Effects -- BodySpec

GHK-Cu Peptide

• GHK-Cu Peptide -- Innerbody
• GHK-Cu Regenerative Actions -- PMC
• GHK-Cu Side Effects -- Amazing Meds
• GHK-Cu Side Effects -- Peptides.org

NAD+ Injection

• NAD IV Therapy Safety -- Peach IV
• NAD+ Injection SOP -- Walnut Creek Aesthetics
• NAD+ Injection -- Empower Pharmacy
• NAD Injections Guide -- Jinfiniti

Methylene Blue

• Methylene Blue -- StatPearls / NCBI
• Methylene Blue -- Mayo Clinic
• Methylene Blue -- GoodRx
• Methylene Blue Interactions -- GoodRx
• Methylene Blue -- Harvard Health

Vitamin B12 / Methylcobalamin Injection

• Vitamin B12 -- NIH Health Professional Fact Sheet
• Methylcobalamin -- Drugs.com
• Vitamin B12 -- StatPearls / NCBI
• Vitamin B12 Injection -- Drugs.com

B-Complex Injection

• Vitamin B Complex Prescribing Information -- Drugs.com
• Vitamin B Complex Injection -- DailyMed
• Compounded Vitamin B-Complex -- Empower Pharmacy

L-Carnitine Injection

• L-Carnitine -- Mayo Clinic
• L-Carnitine Side Effects -- Drugs.com
• Carnitine -- NIH Health Professional Fact Sheet
• Levocarnitine -- Medscape

Glutathione Injection

• Glutathione Safety for Skin Lightening -- PMC
• Glutathione -- WebMD
• Glutathione -- Drugs.com
• Glutathione for Skin Lightening Review -- PMC

Biotin Injection

• Biotin -- StatPearls / NCBI
• Biotin -- NIH Health Professional Fact Sheet
• Biotin Side Effects -- Cleveland Clinic
• Compounded Biotin Injection -- Empower Pharmacy

MIC Lipotropic Injection

• MIC Injections -- IAPAM
• Lipotropic Injections -- Healthline
• Lipo-B Injection -- Empower Pharmacy

Immune Boost / Tri-Immune Injection

• Tri-Immune Boost -- Wilson Aesthetics
• Tri-Immune Boost -- BioEnve

Arginine Injection

• Arginine -- Mayo Clinic
• Arginine -- Medscape
• Arginine -- RxList
• L-Arginine -- Mayo Clinic (supplement)

Scream Cream

• Scream Cream ISI -- Superior Health Wellness
• Safety of Topical Sildenafil Cream -- Journal of Sexual Medicine
• Compounded Arousal Cream -- Empower Pharmacy
• Scream Cream Review -- Journal of Sexual Medicine (Scoping Review)